

**TSH BIOPHARM CORPORATION LTD.  
AND SUBSIDIARIES  
Consolidated Financial Statements  
With Independent Auditors' Report  
For the Years Ended December 31, 2025 and 2024**

**Address : 3F.-1, No. 3-1, Park St., Nangang Dist., Taipei City 115, Taiwan (R.O.C.)**

**Telephone No. : 02-26558525**

---

For the convenience of readers and for information purpose only, the independent auditors' report and the accompanying financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. In the event of any discrepancy between the English version and the original Chinese version or any difference in the interpretation of the two versions, the Chinese-language independent auditors' report and financial statements shall prevail.

## Table of contents

Contents	Page
1.Cover Page	1
2.Table of Contents	2
3.Representation Letter	3
4.Independent Auditors’ Report	4~8
5.Balance Sheets	9
6.Statements of Comprehensive Income	10
7.Statements of Changes in Equity	11
8.Statements of Cash Flows	12~13
9.Notes to the Financial Statements	14
(1) History and organization	14
(2) Approval date and procedures of the financial statements	14
(3) Application of new standards, amendments and interpretations	14~15
(4) Summary of significant accounting policies	16~28
(5) Significant accounting assumptions and judgments, and major sources of estimation uncertainty	29
(6) Explanation of significant accounts	29~55
(7) Related-party transactions	55~57
(8) Pledged assets	57
(9) Significant commitments and contingencies	57
(10) Losses due to major disasters	57
(11) Significant subsequent Events	57
(12) Other	57
(13) Other disclosures	58
A. Information on significant transactions	58~59
B. Information on investees	59
C. Information on investment in mainland China	59
(14) Segment information	59~61

## **Representation Letter**

The entities that are required to be included in the combined financial of TSH Biopharm Corporation Limited as of and for the year ended December 31, 2025 under the Criteria Governing the Preparation of Affiliation Reports, Consolidated Business Reports, and Consolidated Financial Statements of Affiliated Enterprises are the same as those included in the financial statements prepared in conformity with International Financial Reporting Standards No. 10 endorsed by the Financial Supervisory Commission, “Consolidated Financial Statements.” In addition, the information required to be disclosed in the combined financial statements is included in the consolidated financial statements. Consequently, TSH Biopharm Corporation Limited and Subsidiaries do not prepare a separate set of combined financial statements.

Company name : TSH Biopharm Corporation Limited

Chairman: Lin-Chuan

Date: March 5, 2026

## INDEPENDENT AUDITORS' REPORT

To the Board of Directors of TSH Biopharm Corporation Ltd.

### Opinion

We have audited the accompanying consolidated balance sheets of TSH Biopharm Corporation Ltd. and its subsidiaries (the "Group"), which comprise the balance sheets as of December 31, 2025 and 2024, the consolidated statements of comprehensive income, changes in equity, and cash flows for the years ended December 31, 2025 and 2024, and notes to the consolidated financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Group as of December 31, 2025 and 2024 and its consolidated financial performance and its consolidated cash flows for the years then ended in accordance with the "Regulations Governing the Preparation of Financial Reports by Securities Issuers" and with the International Financial Reporting Standards, International Accounting Standards, IFRIC Interpretations, and SIC Interpretations endorsed and issued into effect by the Financial Supervisory Commission.

### Basis for Opinion

We conducted our audit in accordance with the "Regulations Governing Auditing and Certification of Financial Statements by Certified Public Accountants" and the auditing standards generally accepted in the Republic of China. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Group in accordance with the Certified Public Accountants Code of Professional Ethics in Republic of China ("the Code"), and we have fulfilled our other ethical responsibilities in accordance with the Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. Key audit matters for the consolidated financial statements in the current period are stated as follow:

#### 1. Sales Revenue

Please refer to Note 4(13) of the financial statements for the accounting principles on revenue

recognition. Please refer to Note 6(17) of the financial statements for the details on revenue recognition.

Description of key audit matter:

The Group's sales is mainly from the selling of pharmaceuticals and chemical drugs. Because the customers are diversity and numerous, it takes longer time to verify sales transactions. Therefore, the occurrence of sales transactions is one of the important issues in performing our audit procedures.

How the matter was addressed in our audit:

Auditing procedures performed include testing the effectiveness of the design and implementing the internal control system of sales and collection operation ; testing the samples of sales transactions before and after the balance sheet date to ensure the correctness of sales revenue and inspecting the related documents to ensure the adequacy and reasonableness of revenue recognition. The auditor also assessed whether the disclosure items related to revenue recognition in the consolidated financial statements are appropriate.

## 2. Valuation of Inventories

Please refer to notes 4(8), 5 and 6(4) of the notes to the consolidated financial statement for the accounting policies on measuring inventory, assumptions used and uncertainties considered in determining net realizable value, allowances for impairment loss and obsolescence and balances of impairment loss and obsolescence, respectively.

Description of key audit matter:

Inventories are stated at cost and net realizable value. Due to fierce competition in the pharmaceutical industry and the declining prices of health insurance drugs every year, which will affect the sales prices of related products, resulting in a risk that the cost of inventories will exceed its net value. Therefore, inventory evaluation is one of the key audit matters for our audit.

How the matter was addressed in our audit:

Our audit procedures for the above key audit matters included assessing the Group's inventory allowance amount based on the nature of the inventories; performing audit to check the correctness of the inventory age report; reviewing the Group's past inventory allowances and assessing whether the estimation methods and assumptions are appropriate; observing the inventory count and checking the inventory status to assess whether the inventory is expired or damaged; sampling the latest sales prices of inventory and assessing the reasonableness of net realizable value; assessing whether disclosure items for inventory allowances are appropriate.

## 3. Valuation of Goodwill Impairment

Please refer to notes 4(12) Impairment of Non-financial Assets of the notes to the consolidated financial statement for the accounting policies on impairment assessments of intangible assets, notes 5(2) of the notes to the consolidated financial statement for the accounting estimates and assumptions concerning goodwill, and notes 6(9) Intangible Assets of the notes to the consolidated financial statement for further explanations regarding goodwill impairment assessments

Description of key audit matter:

The goodwill of the Group accounts for 12.7% of the total assets. The primary risk lies in the management's subjective judgment when assessing future cash flow assumptions, which carry a high degree of uncertainty and may affect the evaluation of recoverable value. Therefore, the goodwill impairment test is one of the most critical evaluation matters in the audit of the Group's financial statements.

How the matter was addressed in our audit:

Our audit procedures for the above key audit matters included obtaining externally available information to validate management's assumptions and performing professional evaluations of the key parameters applied by management, including the projected growth rate, discount rate, and gross margin. In addition, we assessed the accuracy of management's historical forecasts and performed sensitivity analyses on the assumptions used in the impairment testing calculations.

### **Other Matter**

TSH Biopharm Corporation Ltd. has prepared the parent company only financial statements for the years 2025 and 2024, and they have been audited by our accountants who issued unqualified opinions with an emphasis of matter paragraph and unqualified opinions, respectively. The audit reports are on file for reference.

### **Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Statements**

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with Regulations Governing the Preparation of Financial Reports by Securities Issuers and the International Financial Reporting Standards, International Accounting Standards, IFRIC Interpretations, and SIC Interpretations as endorsed by the Financial Supervisory Commission and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern, and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

Those charged with governance (including of the Audit Committee) are responsible for overseeing the Group's financial reporting process.

### **Auditor's Responsibilities for the Audit of the Consolidated Financial Statements**

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements

as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the auditing standards generally accepted in the Republic of China will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with auditing standards generally accepted in the Republic of China, we exercised professional judgment and maintained professional skepticism throughout the audit. We also:

1. Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.
3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
4. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
5. Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
6. Obtain sufficient and appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements.

We are responsible for the direction, supervision and performance of the audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identified during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

The engagement partners on the audit resulting in this independent auditor's report are Yilien Han and Shin- Ting Huang.

KPMG  
Taipei, Taiwan (Republic of China)  
March 5, 2026

-----  
The accompanying consolidated financial statements are not intended to present the financial position and results of operations and cash flows in accordance with accounting principles generally accepted in countries and jurisdictions other than the Republic of China. The standards, procedures and practices in the Republic of China governing the audit of such financial statements may differ from those generally accepted in countries and jurisdictions other than the Republic of China. Accordingly, the accompanying consolidated financial statements and report of independent accountants are not intended for use by those who are not informed about the accounting principles or auditing standards generally accepted in the Republic of China, and their applications in practice.

(English Translation of the Consolidated Financial Statements Originally Issued in Chinese)  
**TSH Biopharm Corporation Ltd. and Subsidiaries**  
**Consolidated Balance Sheets**  
**December 31, 2025 and 2024**  
(Expressed in thousands of New Taiwan Dollars)

		December 31, 2025		December 31, 2024				December 31, 2025		December 31, 2024	
Assets		Amount	%	Amount	%	Liabilities and Equity		Amount	%	Amount	%
<b>Current assets:</b>						<b>Current liabilities:</b>					
1100	Cash and cash equivalents (notes 6(1) 、(5) and (20))	\$ 464,539	24	588,342	32	2130	Contract liabilities-current (note 6(17))	\$ 3,242	-	1,039	-
1120	Current financial assets at fair value through other comprehensive income (notes 6(2) 、(20) and 13)	30,743	2	77,015	4	2150	Notes payable (note 6(5) and (20))	7,796	1	16,532	1
1150	Notes receivable, net (notes 6(3) 、(5) 、(17) and (20))	13,173	1	11,023	1	2170	Accounts payable (note 6(5) and (20))	14,978	1	18,057	1
1170	Accounts receivable, net (notes 6(3) 、(5) 、(17) and (20))	291,805	15	199,483	11	2180	Accounts payable to related parties (notes 6(20) and 7)	25,851	1	36,766	2
1180	Accounts receivable from related parties (notes 6(3) 、(17) 、(20) and 7)	7,365	-	1,177	-	2200	Other payables (notes 6(11) 、(20) and 7)	108,062	6	90,708	5
1220	Current income tax assets	372	-	205	-	2230	Current income tax liabilities (note 6(5))	26,676	1	32,232	1
1200	Other receivables (notes 6(20))	1,978	-	2,182	-	2280	Current lease liabilities (notes 6(5) 、(12) 、(20) 、(23) and 7)	11,945	1	10,101	-
130x	Inventories (note 6(4) and (5))	155,741	8	176,075	10	2300	Other current liabilities (note 6(5))	28,541	1	3,460	-
1410	Prepayments	18,536	1	16,788	1			<u>227,091</u>	<u>11</u>	<u>208,895</u>	<u>10</u>
1476	Other financial assets-current (notes 6(1) 、(5) 、(10) and (20))	437,000	22	232,000	13						
1479	Other current assets –other (notes 6(10))	1,768	-	412	-						
		<u>1,423,020</u>	<u>73</u>	<u>1,304,702</u>	<u>72</u>						
<b>Non-current assets:</b>						<b>Non-current liabilities:</b>					
1517	Non-current financial assets at fair value through other comprehensive income (notes 6(2) 、(20) and 13)	179,145	9	186,213	10	2580	Non-current lease liabilities (notes 6(5) 、(12) 、(20) 、(23) and 7)	6,695	-	10,330	1
1600	Property, plant and equipment (note 6(5) and (7))	17,218	1	19,989	1		<b>Total liabilities</b>	<u>233,786</u>	<u>11</u>	<u>219,225</u>	<u>11</u>
1755	Right-of-use assets (note 6 (5) and (8))	18,426	1	20,425	1						
1780	Intangible assets (note 6 (5) and (9))	289,477	15	287,652	16		<b>Equity (note 6(15)) :</b>				
1840	Deferred income tax assets (note 6 (14))	2,668	-	4,015	-	3100	Capital stock	383,981	20	383,981	21
1915	Prepayment for equipment	7,192	-	4,030	-	3200	Capital surplus	459,613	24	459,554	25
1920	Refundable deposits paid (notes 6(10) 、(20) and 7)	9,609	1	8,750	-	3310	Retained earnings :				
1995	Other non-current assets (notes 6(5) 、(10) and 9)	4,699	-	6,417	-	3350	Legal reserve	158,200	8	126,073	7
		<u>528,434</u>	<u>27</u>	<u>537,491</u>	<u>28</u>	3400	Unappropriated retained earnings	423,000	22	354,605	19
							Other equity	17,815	1	67,579	4
							Equity attributable to owners of the parent company	1,442,609	75	1,391,792	76
						36xx	Non-controlling interest (note 6(5) and (6))	275,059	14	231,176	13
							<b>Total equity</b>	1,717,668	89	1,622,968	89
<b>Total assets</b>		<u>\$ 1,951,454</u>	<u>100</u>	<u>1,842,193</u>	<u>100</u>	<b>Total liabilities and equity</b>		<u>\$ 1,951,454</u>	<u>100</u>	<u>1,842,193</u>	<u>100</u>

See accompanying notes to financial statements.

(English Translation of the Consolidated Financial Statements Originally Issued in Chinese)  
**TSH Biopharm Corporation Ltd. and Subsidiaries**  
**Consolidated Statements of Comprehensive Income**  
**For the years ended December 31, 2025 and 2024**  
(Expressed in Thousands of New Taiwan Dollars, Except for Earnings Per Share)

	2025		2024	
	AMOUNT	%	AMOUNT	%
4000 <b>Operating revenue</b> (notes 6(17) and 7)	\$ 1,336,523	100	\$ 1,115,716	100
5000 <b>Operating costs</b> (notes 6(4)、(13) and 7)	655,785	49	532,954	48
	<u>680,738</u>	<u>51</u>	<u>582,762</u>	<u>52</u>
	<b>Gross profit</b>			
6000 <b>Operating expenses</b> (notes 6(3)、(9)、(12)、(13)、(18)、7 and 12):				
6100 Selling expenses	320,833	24	249,473	22
6200 Administrative expenses	116,024	9	134,683	12
6300 Research and development expenses	24,615	2	27,987	3
6450 Expected credit loss	896	-	763	-
	<u>462,368</u>	<u>35</u>	<u>412,906</u>	<u>37</u>
	<u>218,370</u>	<u>16</u>	<u>169,856</u>	<u>15</u>
	<b>Operating income</b>			
	<b>Non-operating income and expenses</b> (notes 6(12)、(19) and 7):			
7100 Interest income	8,274	1	5,456	-
7010 Other income	2,256	-	2,302	-
7020 Other gains and losses	6,684	1	( 3,725 )	-
7050 Finance costs	( 797 )	-	( 456 )	-
	<u>16,417</u>	<u>2</u>	<u>3,577</u>	<u>-</u>
	<u>234,787</u>	<u>18</u>	<u>173,433</u>	<u>15</u>
7950 <b>Income tax expense</b> (note 6(14))	( 46,969 )	( 4 )	( 39,285 )	( 4 )
	<u>\$ 187,818</u>	<u>14</u>	<u>\$ 134,148</u>	<u>11</u>
8300 <b>Other comprehensive income</b>				
8310 <b>Components of other comprehensive income that will not be reclassified to profit or loss</b>				
8316 Unrealized gains (losses) from investments in equity instruments at fair value through other comprehensive income	( 7,293 )	( 1 )	220,157	20
8349 Income tax related to components of other comprehensive income that will not be reclassified to profit or loss	-	-	-	-
	<u>( 7,293 )</u>	<u>( 1 )</u>	<u>220,157</u>	<u>20</u>
8360 <b>Components of other comprehensive income that may be reclassified subsequently to profit or loss</b>				
8361 Exchange differences on translation of foreign financial statements	380	-	73	-
8399 Income tax related to components of other comprehensive income that may be reclassified to profit or loss	-	-	-	-
	<u>( 6,913 )</u>	<u>( 1 )</u>	<u>220,230</u>	<u>20</u>
8300 <b>Other comprehensive income (after tax)</b>				
8500 <b>Total comprehensive income</b>	<u>\$ 180,905</u>	<u>13</u>	<u>\$ 354,378</u>	<u>31</u>
	<b>Profit attributable to:</b>			
8610 Equity holders of the parent company	\$ 139,260	10	\$ 113,093	9
8620 Non-controlling interest	48,558	4	21,055	2
	<u>\$ 187,818</u>	<u>14</u>	<u>\$ 134,148</u>	<u>11</u>
	<b>Total comprehensive income attributable to:</b>			
8710 Equity holders of the parent company	\$ 132,162	9	\$ 333,288	29
8720 Non-controlling interest	48,743	4	21,090	2
	<u>\$ 180,905</u>	<u>13</u>	<u>\$ 354,378</u>	<u>31</u>
	<b>Earnings per share</b> (note 6(16))			
9750 <b>Basic earnings per share</b>	<u>\$ 3.63</u>		<u>\$ 2.95</u>	
9850 <b>Diluted earnings per share</b>	<u>\$ 3.62</u>		<u>\$ 2.94</u>	

See accompanying notes to financial statements.

(English Translation of the Consolidated Financial Statements Originally Issued in Chinese)  
**TSH Biopharm Corporation Ltd. and Subsidiaries**  
**Consolidated Statements of Changes in Equity**  
**For the years ended December 31, 2025 and 2024**  
(Expressed in Thousands of New Taiwan Dollars)

	Retained Earnings					Other Equity Interest				
	Ordinary share capital	Capital surplus	Legal reserve	Special reserve	Unappropriated retained earnings	Cumulative translation differences of foreign operations	Unrealized gain(loss) on financial assets at fair value through other comprehensive income	Equity attributable to owners of the parent company	Non- controlling interest	Total equity
<b>Balance at January 1, 2024</b>	\$ 383,981	459,500	121,910	4,417	82,232	( 233)	55,793	1,107,600	158,633	1,266,233
Net income for the year	-	-	-	-	113,093	-	-	113,093	21,055	134,148
Other comprehensive income for the year	-	-	-	-	-	38	220,157	220,195	35	220,230
Total comprehensive income for the year	-	-	-	-	113,093	38	220,157	333,288	21,090	354,378
Distribution of retained earnings :										
Legal reserve	-	-	4,163	-	( 4,163)	-	-	-	-	-
Cash dividends	-	-	-	-	( 49,150)	-	-	( 49,150)	-	( 49,150)
Special reserve	-	-	-	( 4,417)	4,417	-	-	-	-	-
Other changes in capital surplus	-	54	-	-	-	-	-	54	-	54
Change in non-controlling interest	-	-	-	-	-	-	-	-	51,453	51,453
Disposal of equity instruments measured at fair value through other comprehensive income	-	-	-	-	208,176	-	( 208,176)	-	-	-
<b>Balance at December 31, 2024</b>	383,981	459,554	126,073	-	354,605	( 195 )	67,774	1,391,792	231,176	1,622,968
Net income for the year	-	-	-	-	139,260	-	-	139,260	48,558	187,818
Other comprehensive income for the year	-	-	-	-	-	195	( 7,293)	( 7,098)	185	( 6,913)
Total comprehensive income for the year	-	-	-	-	139,260	195	( 7,293)	132,162	48,743	180,905
Distribution of retained earnings :										
Legal reserve	-	-	32,127	-	( 32,127)	-	-	-	-	-
Cash dividends	-	-	-	-	( 81,404)	-	-	( 81,404)	-	( 81,404)
Other changes in capital surplus :										
Other changes in capital surplus	-	59	-	-	-	-	-	59	-	59
Dividends distributed by subsidiaries to non-controlling interests	-	-	-	-	-	-	-	-	( 4,860)	( 4,860)
Disposal of equity instruments measured at fair value through other comprehensive income	-	-	-	-	42,666	-	( 42,666)	-	-	-
<b>Balance at December 31, 2025</b>	\$ 383,981	459,613	158,200	-	423,000	-	17,815	1,442,609	275,059	1,717,668

See accompanying notes to financial statements.

(English Translation of the Consolidated Financial Statements Originally Issued in Chinese)  
**TSH Biopharm Corporation Ltd. and Subsidiaries**  
**Consolidated Statements of Cash Flows**  
**For the years ended December 31, 2025 and 2024**  
(Expressed in Thousands of New Taiwan Dollars)

	<b>2025</b>	<b>2024</b>
<b>Cash flows from operating activities:</b>		
<b>Profit before tax</b>	\$ 234,787	\$ 173,433
<b>Adjustments:</b>		
Adjustments to reconcile profit		
Depreciation	16,555	18,268
Amortization	10,181	10,685
Expected credit loss	896	763
Interest expense	797	456
Interest income	( 8,274 )	( 5,456 )
Dividend income	( 6,557 )	( 6,528 )
Loss on disposal of property, plant and equipment	-	867
Gain on disposal of subsidiaries	( 1,113 )	-
Impairment loss	-	8,799
Loss on lease modification	-	( 6 )
Total adjustment to reconcile profit	12,485	27,848
Changes in operating assets and liabilities:		
Decrease (increase) in notes receivable	( 2,150 )	8,055
Decrease (increase) in accounts receivable (including related parties)	( 99,406 )	48,606
Decrease (increase) in other receivables	188	( 588 )
Decrease (increase) in inventories	20,334	( 44,911 )
Increase in other current assets	( 4,881 )	( 913 )
Increase (decrease) in contract liabilities	2,212	( 803 )
Increase (decrease) in notes payable (including related parties)	( 8,736 )	14,572
Decrease in accounts payable(including related parties)	( 13,994 )	( 43,137 )
Increase in other payables	17,392	15,534
Increase (decrease) in other current liabilities	25,140	( 259 )
Total changes in operating assets and liabilities	( 63,901 )	( 3,844 )
Total adjustments	( 51,416 )	24,004
Cash flows from operations	183,371	197,437
Interest received	8,290	6,027
Interest paid	( 797 )	( 456 )
Income tax paid	( 51,344 )	( 19,240 )
<b>Net cash flows from operating activities</b>	<b>139,520</b>	<b>183,768</b>

(Continued)

(English Translation of the Consolidated Financial Statements Originally Issued in Chinese)  
**TSH Biopharm Corporation Ltd. and Subsidiaries**  
**Consolidated Statements of Cash Flows**  
**For the years ended December 31, 2025 and 2024**  
(Expressed in Thousands of New Taiwan Dollars)

	<b>2025</b>	<b>2024</b>
<b>Cash flows from (used in) investing activities:</b>		
Proceeds from acquisition of financial assets at fair value through other comprehensive income	\$ -	(\$ 2,489)
Proceeds from disposal of financial assets at fair value through other comprehensive income	46,047	221,121
Acquisition of subsidiaries (net of cash acquired)	-	( 242,870)
Disposal of subsidiaries	1,471	-
Acquisition of property, plant and equipment	( 1,357)	( 846)
Disposal of property, plant and equipment	-	295
Acquisition of intangible assets	( 5,884)	( 1,018)
Decrease (increase) in guarantee deposits paid	( 859)	466
Increase in other financial assets - current	( 205,000)	( 90,691)
Increase in other non-current assets	( 2,630)	-
Increase in prepayment for equipment	( 3,162)	( 879)
Dividends received	6,557	6,528
<b>Net cash flows used in investing activities</b>	<b>( 164,817)</b>	<b>( 110,383)</b>
<b>Cash flows used in financing activities:</b>		
Payments of lease liabilities	( 12,242)	( 12,535)
Cash dividends paid	( 81,404)	( 49,150)
Dividends paid to non-controlling interests	( 4,860)	-
<b>Net cash flows used in financing activities</b>	<b>( 98,506)</b>	<b>( 61,685)</b>
Effect of fluctuations in exchange rate	-	57
Net increase in cash and cash equivalents	( 123,803)	11,757
Cash and cash equivalents at beginning of year	588,342	576,585
Cash and cash equivalents at end of year	<b>\$ 464,539</b>	<b>\$ 588,342</b>

See accompanying notes to financial statements.

(English Translation of the Consolidated Financial Statements Originally Issued in Chinese)  
**TSH BIOPHARM CORPORATION LTD. and Subsidiaries**  
**Notes to the Consolidated Financial Statements**  
**December 31, 2025 and 2024**

(Amounts expressed in thousands of New Taiwan Dollars unless otherwise specified)

**1. History and organization**

TSH Biopharm Corporation Ltd. (the “Company”) was incorporated on September 21, 2010. The Company's registered office address is 3F.-1, No. 3-1, Park St., Nangang Dist., Taipei City 115, Taiwan (R.O.C.). The shares of the Company have been listed on the Taipei Exchange (“TPEX”) since April 2012. The main activity of the Company and its subsidiaries (the “Group”) is in sale of a variety of pharmaceuticals, chemical drugs and engaged in biotechnology services.

**2. Approval date and procedures of the financial statements**

The accompanying consolidated financial statements were authorized for issue by the Board of Directors on March 5, 2026.

**3. Application of new standards, amendments and interpretations**

(1) The impact of the International Financial Reporting Standards (“IFRSs”) endorsed by the Financial Supervisory Commission, R.O.C. (“FSC”) which have already been adopted.

The Group believes that the adoption of the following IFRSs from January 1, 2025 would not have any material impact on its consolidated financial statements.

- Amendments to IAS 21 “Lack of Exchangeability”

(2) The impact of the International Financial Reporting Standards (“IFRSs”) endorsed by the Financial Supervisory Commission, R.O.C. (“FSC”) which have not been adopted.

The assessment of the Group’s application of the newly amended IFRSs, effective from January 1, 2026, indicates that it will not have a significant impact on the consolidated financial statements.

- IFRS 17 “Insurance Contracts” and amendments to IFRS 17 “Insurance Contracts”
- Amendments to IFRS 9 and IFRS 7 “Amendments to the Classification and Measurement of Financial Instruments”
- Annual Improvements to IFRS Accounting Standards
- Amendments to IFRS 9 and IFRS 7 “Contracts for Renewable Electricity”

(3) The impact of IFRS issued by IASB but not yet endorsed by the FSC

The IASB has issued standards and interpretations that have not yet been endorsed by the FSC. The potential impact on the Group is as follows:

<u>Newly issued or revised standards</u>	<u>Major revisions</u>	<u>Effective Date of the Council's Publication</u>
IFRS 18 “Presentation and Disclosure in Financial Statements”	The new standard introduces three types of income and expenses, two subtotal items in the income statement, and a single note regarding management performance measurement. These three amendments strengthen guidance on how information is disaggregated in financial statements, providing users with better and more consistent information, and will impact all companies.	January 1, 2027

Newly issued or revised standards	Major revisions	Effective Date of the Council's Publication
IFRS 18 “Presentation and Disclosure in Financial Statements”	<ul style="list-style-type: none"> <li>• More Structured Income Statement: Under current standards, companies use different formats to express their operating results, making it difficult for investors to compare the financial performance of different companies. The new standard adopts a more structured income statement, introducing a subtotal of "operating profit" based on new definitions and stipulating that all income and expenses be classified into three new distinct categories based on the company's primary operating activities.</li> <li>• Management Performance Measurement (MPMs): The new standard introduces the definition of Management Performance Measurement and requires companies to explain in a single note to the financial statements for each performance measure why it provides useful information, how it is calculated, and how the measure is adjusted to reconcile with the amounts recognized under International Financial Reporting Standards accounting standards.</li> <li>• More Detailed Information: The new standard includes guidance on how companies should enhance the grouping of information in financial statements. This includes guidance on whether information should be included in the primary financial statements or further disaggregated in the notes.</li> </ul>	<p>January 1, 2027</p> <p>Note: On September 25, 2025, the FSC announced in a press release that publicly traded companies will be required to adopt IFRS 18 starting from fiscal year 2028. Furthermore, enterprises that wish to early adopt IFRS 18 may do so—subject to FSC approval—once IFRS 18 has been formally endorsed by the FSC.</p>

The Group is currently assessing the impact of the aforementioned standards and interpretations on the financial position and operating results of the consolidated company. Relevant impacts will be disclosed upon completion of the assessment.

The Group anticipates that the following additional yet to be endorsed new releases and amendments will not have a significant impact on the consolidated financial statements.

- Amendments to IFRS 10 and IAS 28 “Sale or Contribution of Assets Between an Investor and Its Associate or Joint Venture”
- IFRS 19 “Subsidiaries without Public Accountability: Disclosures”
- Amendments to IFRS 21 “Translation to a Hyperinflationary Presentation Currency”

#### 4. Summary of significant accounting policies

The significant accounting policies applied in the preparation of these consolidated financial statements are summarized as follows. Except for those described individually, the significant accounting policies have been applied consistently to all periods presented in these consolidated financial statements.

##### (1) Statement of compliance

These consolidated financial statements have been prepared in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers (hereinafter referred to as “the Regulations”) and the International Financial Reporting Standards, International Accounting Standards, IFRIC Interpretations, and SIC Interpretations endorsed and issued into effect by the Financial Supervisory Commission, R.O.C. (hereinafter referred to as “IFRSs endorsed by FSC”).

##### (2) Basis of preparation

###### A. Basis of measurement

The consolidated financial statements have been prepared on a historical cost basis except for financial assets at fair value through other comprehensive income are measured at fair value.

###### B. Functional and presentation currency

The functional currency of the Group is determined based on the primary economic environment in which the entity operates. The consolidated financial statements are presented in New Taiwan Dollars (NTD), which is the Group’s functional currency. All financial information presented in NTD has been rounded to the nearest thousand unless otherwise stated.

##### (3) Basis of consolidation

###### A. Principles for preparation of consolidated financial statements:

All subsidiaries are included in the Group’s consolidated financial statements. Subsidiaries are all entities (including structured entities) controlled by the Group. The Group controls an entity when the Group is exposed, or has rights, to variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity.

Consolidation of subsidiaries begins from the date the Group obtains control of the subsidiaries and ceases when the Group loses control of the subsidiaries. Inter-company transactions, balances and unrealized gains or losses on transactions between companies within the Group are eliminated. Profit or loss and each component of other comprehensive income are attributed to the owners of the parent and to the non-controlling interests. Total comprehensive income is attributed to the owners of the parent and to the non-controlling interests even if this results in the non-controlling interests having a deficit balance.

Accounting policies of subsidiaries have been adjusted where necessary to ensure consistency with the policies adopted by the Group.

Changes in a parent’s ownership interest in a subsidiary that do not result in the parent losing control of the subsidiary are accounted for as equity transactions. Any difference between the amount by which the non-controlling interests are adjusted and the fair value of the consideration paid or received is recognized directly in equity.

B. Subsidiaries included in the consolidated financial statements:

<u>Name of Investor</u>	<u>Name of subsidiary</u>	<u>Main Business Activities</u>	<u>Percentage of Ownership</u>		<u>Note</u>
			<u>December 31, 2025</u>	<u>December 31, 2024</u>	
TSH Biopharm Corporation Ltd.	Chuang Yi Biotech Co. Ltd.	Selling of health food	51.60%	51.60%	
TSH Biopharm Corporation Ltd.	Top Pharma Medical-wares Co., Ltd.	Selling of medicine and dietary supplement	51.00%	51.00%	Note 1、2
TSH Biopharm Corporation Ltd.	TOP Biological Technology Company Limited.	Food manufacturing industry	-%	51.00%	Note 1、2
Chuang Yi Biotech Co. Ltd.	Immortal Fame Global Ltd.	General export trade and investment in various production enterprises	-%	100.00%	Note 3
Immortal Fame Global Ltd.	Chuang Yi (Shanghai) Trading Co., Ltd	Selling of dietary supplement	-%	100.00%	Note 3

Note 1 : On March 11, 2024, the Company acquired 51% of the issued and outstanding common shares of Top Pharma Medical-wares Co., Ltd. and TOP Biological Technology Company Limited. by resolution of the board of directors, and completed the share delivery on April 9, 2024.

Note 2 : To strengthen the integration of group resources, the Company's Board of Directors approved the merger of Top Pharma Medical-wares Co., Ltd. and TOP Biological Technology Company Limited on November 8, 2024, with Top Pharma Medical-wares Co., Ltd. as the surviving company and TOP Biological Technology Company Limited as the dissolved company. The merger effective date was set on January 1, 2025, and the change was approved by the competent authority on March 3, 2025.

Note 3 : The Company resolved, through the Board of Directors, to dispose of the company, and the transaction was completed on January 6, 2025.

C. Subsidiaries not included in the consolidated financial statements: None.

(4) Foreign currency

A. Foreign currencies transactions

Transactions in foreign currencies are translated into the respective functional currencies using the exchange rates at the dates of the transactions. At the end of each subsequent reporting period, monetary items denominated in foreign currencies are re-translated at the exchange rate prevailing at reporting date. Non-monetary items denominated in foreign currencies that are measured at fair value are translated into the functional currencies using the exchange rate at the date that the fair value was determined. Non-monetary items denominated in foreign currencies that are measured based on historical cost are translated using the exchange rate at the date of the transaction.

Exchange differences are generally recognized in profit or loss, except for those differences relating to the following, which are recognized in other comprehensive income:

- an investment in equity securities designated as at fair value through other comprehensive income;
- a financial liability designated as a hedge of the net investment in a foreign operation to the extent that the hedge is effective; or
- qualifying cash flow hedges to the extent that the hedges are effective.

B. Foreign Operation

The assets and liabilities of foreign operations, including goodwill and fair value adjustments arising on acquisition, are translated into New Taiwan Dollar at the exchange rates at the reporting date. The income and expenses of foreign operations are translated into New Taiwan Dollar at average exchange rate of the period. Exchange differences are recognized in other comprehensive income.

When a foreign operation is disposed of such that control, significant influence, or joint control is lost, the cumulative amount in the translation reserve related to that foreign operation is reclassified to profit or loss in current period. When the Group disposes of only part of its interest in a subsidiary that includes a foreign operation while retaining control, the relevant proportion of the cumulative amount is reattributed to non-controlling interests. When the Group disposes of only part of its investment in an associate or joint venture that includes a foreign operation while retaining significant influence or joint control, the relevant proportion of the cumulative amount is reclassified to profit or loss in current period.

When the settlement of a monetary receivable from or payable to a foreign operation is neither planned nor likely to occur in the foreseeable future, exchange differences arising from such a monetary item that are considered to form part of the net investment in the foreign operation are recognized in other comprehensive income.

#### (5) Classification of current and non-current assets and liabilities

The Group classifies an asset as current when any one of the following requirements is met. Assets that are not classified as current are non-current assets.

- A. It expects to realize the asset, or intends to sell or consume it, in its normal operating cycle;
- B. It holds the asset primarily for the purpose of trading;
- C. It expects to realize the asset within twelve months after the reporting period; or
- D. The asset is cash or cash equivalent unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

The Group classifies a liability as current when any one of the following requirements is met. Liabilities that are not classified as current are non-current liabilities.

- A. It expects to settle the liability in its normal operating cycle;
- B. It holds the liability primarily for the purpose of trading;
- C. The liability is due to be settled within twelve months after the reporting period; or
- D. It does not have an unconditional right to defer settlement of the liability for at least twelve months after the reporting period. Terms of a liability that could, at the option of the counterparty, result in its settlement by issuing equity instruments do not affect its classification.

#### (6) Cash and cash equivalents

Cash comprise cash and cash in bank. Cash equivalents are short-term and highly liquid investments that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value. Time deposits which meet the above definition and held for the purpose of meeting short-term cash commitments rather than for investment or other purposes are classified as cash equivalents.

Bank overdrafts that are repayable on demand and form an integral part of the Group's cash management are included as a component of cash and cash equivalents for the purpose of the consolidated statement of cash flows.

#### (7) Financial instruments

Accounts receivables are initially recognized when they are originated. All other financial assets and financial liabilities are initially recognized when the Group becomes a party to the contractual provisions of the instrument. A financial asset (unless it is a trade receivable without a significant financing component) or financial liability is initially measured at fair value plus, for an item not at fair value through profit or loss (FVTPL), transaction costs that are directly attributable to its acquisition or issue. A trade receivable without a significant financing component is initially measured at the transaction price.

#### A. Financial assets

All regular way purchases or sales of financial assets are recognized and derecognized on a trade date basis.

On initial recognition, a financial asset is classified as measured at: amortized cost; Fair value through other comprehensive income (FVOCI) – equity investment. Financial assets are not reclassified subsequent to their initial recognition unless the Group changes its business model for managing financial assets, in which case all affected financial assets are reclassified on the first day of the first reporting period following the change in the business model.

##### (A) Financial assets measured at amortized cost

A financial asset is measured at amortized cost if it meets both of the following conditions and is not designated as measured at FVTPL:

- it is held within a business model whose objective is to hold financial assets to collect contractual cash flows; and
- its contractual terms give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

These assets are subsequently measured at amortized cost, which is the amount at which the financial asset is measured at initial recognition, plus/minus, the cumulative amortization using the effective interest method, adjusted for any loss allowance. Interest income, foreign exchange gains and losses, as well as impairment, are recognized in profit or loss. Any gain or loss on derecognition is recognized in profit or loss.

##### (B) Fair value through other comprehensive income (FVOCI)

On initial recognition of an equity investment that is not held for trading, the Group may irrevocably elect to present subsequent changes in the investment's fair value in other comprehensive income. This election is made on an instrument-by-instrument basis.

Equity investments at FVOCI are subsequently measured at fair value. Dividends are recognized as income in profit or loss unless the dividend clearly represents a recovery of part of the cost of the investment. Other net gains and losses are recognized in other comprehensive income and are never reclassified to profit or loss.

Dividend income is recognized in profit or loss on the date on which the Group's right to receive payment is established.

##### (C) Business model assessment

The Group makes an assessment of the objective of the business model in which a financial asset is held at portfolio level because this best reflects the way the business is managed and information is provided to management. The information considered includes :

- the stated policies and objectives for the portfolio and the operation of those policies in practice. These include whether management's strategy focuses on earning contractual

interest income, maintaining a particular interest rate profile, matching the duration of the financial assets to the duration of any related liabilities or expected cash outflows or realizing cash flows through the sale of the assets;

- how the performance of the portfolio is evaluated and reported to the Group's management;
- the risks that affect the performance of the business model (and the financial assets held within that business model) and how those risks are managed;
- how managers of the business are compensated - e.g. whether compensation is based on the fair value of the assets managed or the contractual cash flows collected; and
- the frequency, volume and timing of sales of financial assets in prior periods, the reasons for such sales and expectations about future sales activity.

Transfers of financial assets to third parties in transactions that do not qualify for derecognition are not considered sales for this purpose, and are consistent with the Group's continuing recognition of the assets.

(D) Assessment whether contractual cash flows are solely payments of principal and interest

For the purposes of this assessment, 'principal' is defined as the fair value of the financial assets on initial recognition. 'Interest' is defined as consideration for the time value of money and for the credit risk associated with the principal amount outstanding during a particular period of time and for other basic lending risks and costs, as well as a profit margin.

In assessing whether the contractual cash flows are solely payments of principal and interest, the Group considers the contractual terms of the instrument. This includes assessing whether the financial asset contains a contractual term that could change the timing or amount of contractual cash flows such that it would not meet this condition. In making this assessment, the Group considers :

- contingent events that would change the amount or timing of cash flows ;
- terms that may adjust the contractual coupon rate, including variable rate features ;
- prepayment and extension features ; and
- terms that limit the Group's claim to cash flows from specified assets ( e.g. nonrecourse features )

(E) Impairment of financial assets

The Group recognizes its loss allowances for expected credit losses (ECL) on financial assets measured at amortized cost (including cash and cash equivalents, notes and accounts receivable, other receivables, guarantee deposit paid and other financial assets).

The Group measures its loss allowances at an amount equal to lifetime ECL, except for the following which are measured as 12-month ECL :

- debt securities that are determined to have low credit risk at the reporting date ; and
- other debt securities and bank balances for which the credit risk (i.e. the risk of default occurring over the expected life of the financial instrument) has not increased significantly since initial recognition.

Loss allowance for trade receivables and contract assets are always measured at an amount equal to lifetime ECL.

When determining whether the credit risk of a financial asset has increased significantly since initial recognition and when estimating ECL, the Group considers reasonable and supportable information that is relevant and available without undue cost or effort. This includes both quantitative and qualitative information and analysis based on the Group's historical experience and informed credit assessment, as well as forward looking information.

Lifetime ECLs are the ECLs that result from all possible default events over the expected life of a financial instrument.

12-month ECLs are the portion of ECLs resulting from default events that are possible within the 12 months after the reporting date (or a shorter period if the expected life of the instrument is less than 12 months).

The maximum period considered when estimating ECLs is the maximum contractual period over which the Group is exposed to credit risk.

ECLs are a probability-weighted estimate of credit losses. Credit losses are measured as the present value of all cash shortfalls (i.e. the difference between the cash flows due to the Group in accordance with the contract and the cash flows that the Group expects to receive). ECLs are discounted at the effective interest rate of the financial asset.

At each reporting date, the Group assesses whether financial assets carried at amortized cost are credit-impaired. A financial asset is "credit-impaired" when one or more events that have a detrimental impact on the estimated future cash flows of the financial asset have occurred. Evidence that a financial asset is credit-impaired includes the following observable data :

- significant financial difficulty of the borrower or issuer ;
- a breach of contract such as a default or being more than 90 days past due ;
- the lender of the borrower, for economic or contractual reasons relating to the borrower's financial difficulty, having granted to the borrower a concession that the lender would not otherwise consider ;
- it is probable that the borrower will enter bankruptcy or other financial reorganization ; or
- the disappearance of an active market for a security because of financial difficulties.

Loss allowances for financial assets measured at amortized cost are deducted from the gross carrying amount of the assets.

The gross carrying amount of a financial asset is written off when the Group has no reasonable expectations of recovering a financial asset in its entirety or a portion thereof. For corporate customers, the Group individually makes an assessment with respect to the timing and amount of write-off based on whether there is a reasonable expectation of recovery. The Group expects no significant recovery from the amount written off. However, financial assets that are written off could still be subject to enforcement activities in order to comply with the Group's procedures for recovery of amounts due.

#### (F) Derecognition of financial assets

The Group derecognizes a financial asset when the contractual rights to the cash flows from the financial asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all of the risks and rewards of ownership of the financial asset are transferred or in which the Group neither transfers nor retains substantially all of the risks and

rewards of ownership and it does not retain control of the financial asset.

The Group enters into transactions whereby it transfers assets recognized in its statement of balance sheet, but retains either all or substantially all of the risks and rewards of the transferred assets. In these cases, the transferred assets are not derecognized.

## B. Financial liabilities and equity instrument

### (A) Classification of debt or equity

Debt and or equity instruments issued by the Group are classified as financial liabilities or equity in accordance with the substance of the contractual arrangements and the definitions of a financial liability and an equity instrument.

### (B) Equity instrument

An equity instrument is any contract that evidences residual interest in the assets of an entity after deducting all of its liabilities. Equity instruments issued are recognized as the amount of consideration received, less the direct cost of issuing.

### (C) Financial liabilities

Financial liabilities are classified as either amortized cost or measured at fair value through profit or loss. Financial liabilities that are held for trading, derivatives, or designated at initial recognition are classified as measured at fair value through profit or loss. Financial liabilities measured at fair value through profit or loss are measured at fair value, with related net gains and losses, including any interest expense, recognized in profit or loss.

Other financial liabilities are subsequently measured at amortized cost using the effective interest method. Interest expenses and exchange gains or losses are recognized in profit or loss. Any gains or losses on derecognition are also recognized in profit or loss.

### (D) Derecognition of financial liabilities

The Group derecognizes a financial liability when its contractual obligations are discharged or cancelled, or expire. The Group also derecognizes a financial liability when its terms are modified and the cash flows of the modified liability are substantially different, in which case a new financial liability based on the modified terms is recognized at fair value.

On derecognition of a financial liability, the difference between the carrying amount of a financial liability extinguished and the consideration paid (including any non-cash assets transferred or liabilities assumed) is recognized in profit or loss.

### (E) Offsetting of financial assets and liabilities

Financial assets and financial liabilities are offset and the net amount presented in the statement of balance sheet when, and only when, the Group currently has a legally enforceable right to set off the amounts and it intends either to settle them on a net basis or to realize the asset and settle the liability simultaneously.

## (8) Inventories

Inventories are measured at the lower of cost and net realizable value. The cost of inventories is based on the weighted-average method and includes expenditure incurred in acquiring the inventories, production or conversion costs, and other costs incurred in bringing them to their present location and condition.

Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and selling expenses.

(9) Property, plant and equipment

A. Recognition and measurement

Items of property, plant and equipment are measured at cost, which includes capitalized borrowing costs, less accumulated depreciation and any accumulated impairment losses.

If significant parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment.

Any gain or loss on disposal of an item of property, plant and equipment is recognized in profit or loss.

B. Subsequent cost

Subsequent expenditure is capitalized only if it is probable that the future economic benefits associated with the expenditure will flow to the Group.

C. Depreciation

Depreciation is calculated on the cost of an asset less its residual value and is recognized in profit or loss on a straight-line basis over the estimated useful lives of each component of an item of property, plant and equipment.

Land is not depreciated.

The estimated useful lives for the current and comparative years of significant items of property, plant and equipment are as follows:

- |                              |              |
|------------------------------|--------------|
| (a) Buildings and structures | 14 ~20 years |
| (b) Machinery equipment      | 2 ~ 10 years |
| (c) Office equipment         | 2 ~ 10 years |
| (d) Other equipment          | 2 ~ 10 years |

Depreciation methods, useful lives, and residual values are reviewed at each reporting date and adjusted if appropriate.

(10) Leases

At inception of a contract, the Group assesses whether a contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

A. As a lessee

The Group recognizes a right-of-use asset and a lease liability at the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received.

The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. In addition, the right-of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain remeasurements of the lease liability.

The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate

cannot be reliably determined, the Group's incremental borrowing rate. Generally, the Group uses its incremental borrowing rate as the discount rate.

Lease payments included in the measurement of the lease liability comprise the following:

- (A) fixed payments, including in-substance fixed payments;
- (B) variable lease payments that depend on an index or a rate, initially measured using the index or rate as at the commencement date;
- (C) amounts expected to be paid under a residual value guarantee; and
- (D) payments for purchase or termination options that are reasonably certain to be exercised.

The lease liability is measured at amortized cost using the effective interest method. It is remeasured when:

- (A) there is a change in future lease payments arising from the change in an index or rate; or
- (B) there is a change in the Group's estimate of the amount expected to be paid under a residual value guarantee; or
- (C) there is a change of its assessment on whether it will exercise an option to purchase the underlying asset, or
- (D) there is a change in the lease term resulting from a change of its assessment on whether it will exercise an extension or termination option; or
- (E) there are any lease modifications

When the lease liability is remeasured, other than lease modifications, a corresponding adjustment is made to the carrying amount of the right-of-use asset, or in profit and loss if the carrying amount of the right-of-use asset has been reduced to zero.

When the lease liability is remeasured to reflect the partial or full termination of the lease for lease modifications that decrease the scope of the lease, the Group accounts for the remeasurement of the lease liability by decreasing the carrying amount of the right-of-use asset to reflect the partial or full termination of the lease, and recognize in profit or loss.

The Group presents right-of-use assets that do not meet the definition of investment and lease liabilities as a separate line item respectively in the statement of financial position.

The Group has elected not to recognize right-of-use assets and lease liabilities for leases of low-value assets, transportation equipment, furniture and fixtures equipment. The Group recognizes the lease payments associated with these leases as an expense on a straight-line basis over the lease term.

## B. As a lessor

When the Group acts as a lessor, it determines at lease commencement whether each lease is a finance lease or an operating lease. To classify each lease, the Group makes an overall assessment of whether the lease transfers to the lessee substantially all of the risks and rewards of ownership incidental to the underlying asset. If this is the case, then the lease is a finance lease; if not, then the lease is an operating lease. As part of this assessment, the Group considers certain indicators such as whether the lease is for the major part of the economic life of the asset.

When the Group is an intermediate lessor, it accounts for its interests in the head lease and the sub-lease separately. It assesses the lease classification of a sub-lease with reference to the right-of-use asset arising from the head lease. If a head lease is a short-term lease to which the Group applies

the exemption described above, then it classifies the sub-lease as an operating lease.

If an arrangement contains lease and non-lease components, the Group applies IFRS 15 to allocate the consideration in the contract.

## (11) Intangible assets

### A. Recognition and measurement

The goodwill arising from the acquisition of a subsidiary is measured at cost less accumulated impairment.

Expenditure on research activities is recognized in profit or loss as incurred.

Development expenditure is capitalized only if the expenditure can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable and the Group intends to, and has sufficient resources to, complete development and to use or sell the asset. Otherwise, it is recognized in profit or loss as incurred. Subsequent to initial recognition, development expenditure is measured at cost, less accumulated amortization and any accumulated impairment losses.

Other intangible assets that are acquired by the Group including patents, computer software and drug permit licenses and have finite useful lives are measured at cost less accumulated amortization and any accumulated impairment losses.

### B. Subsequent expenditure

Subsequent expenditure is capitalized only when it increases the future economic benefits embodied in the specific asset to which it relates. All other expenditure, including expenditure on internally generated goodwill and brands, is recognized in profit or loss as incurred.

### C. Amortization

Except for goodwill, amortization is calculated over the cost of the asset, less its residual value, and is recognized in profit or loss on a straight-line basis over the estimated useful lives of intangible assets from the date that they are available for use.

The estimated useful lives for current and comparative periods are as follows:

(A) Patents and drug permit licenses	3~10 years
(B) Computer software cost	3~10 years
(C) Licence fee for drug distributor	10 years
(D) Trademark rights	10 years

Amortization methods, useful lives and residual values are reviewed at each annual reporting date and adjusted if appropriate.

## (12) Impairment of non-financial assets

At each reporting date, the Group reviews the carrying amounts of its non-financial assets (other than inventories and deferred tax assets) to determine whether there is any indication of impairment. If any such indication exists, then the asset's recoverable amount is estimated. Goodwill is subject to an annual impairment test.

For impairment testing, assets are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or CGUs. Goodwill acquired in a business combination is allocated to each cash-generating unit or group of cash-generating units expected to benefit from the synergies of the combination.

The recoverable amount of an asset or CGU is the greater of its value in use and its fair value less costs to sell. Value in use is based on the estimated future cash flows, discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset or CGU.

An impairment loss is recognized if the carrying amount of an asset or CGU exceeds its recoverable amount. Impairment losses are recognized in profit or loss.

Impairment losses are recognized immediately in the current period's profit or loss and are first allocated to reduce the carrying amount of the goodwill allocated to the cash-generating unit. Any remaining impairment loss is then allocated to reduce the carrying amounts of the other assets within the unit on a pro-rata basis.

Goodwill impairment losses are not reversed. Non-financial assets other than goodwill are only reversed to the extent that the carrying amount does not exceed the amount that would have been determined had no impairment loss been recognized in prior years, adjusted for depreciation or amortization.

### (13) Revenue recognition

Revenue is measured based on the consideration to which the Group expects to be entitled in exchange for transferring goods or services to a customer. The Group recognizes revenue when it satisfies a performance obligation by transferring control of a good or a service to a customer. The accounting policies for the Group's main types of revenue are explained below.

#### A. Sale of goods

The Group recognizes revenue when control of the products has transferred, being when the products are delivered to the customer, the customer has full discretion over the channel and price to sell the products, and there is no unfulfilled obligation that could affect the customer's acceptance of the products. Delivery occurs when the products have been shipped to the specific location, the risks of obsolescence and loss have been transferred to the customer, and either the customer has accepted the products in accordance with the sales contract, the acceptance provisions have lapsed, or the Group has objective evidence that all criteria for acceptance have been satisfied.

A receivable is recognized when the goods are delivered as this is the point in time that the Group has a right to an amount of consideration that is unconditional.

The Group grants its customers the right to return the product. Therefore, the Group reduces revenue by the amount of expected returns and recognizes a refund liability and a right to the returned goods. Accumulated experience is used to estimate such returns at the time of sale at a portfolio level (expected value method). Because the number of products returned has been steady for years, it is highly probable that a significant reversal in the cumulative revenue recognized will not occur. At each reporting date, the Group reassesses the estimated amount of expected returns.

The Group grants allowances to some customers who meet certain conditions. The Group estimates the sales or allowances that may occur based on historical experience and different contract terms, and recognizes refund liabilities accordingly.

#### B. Testing revenue

The Group provides blood tests and other related services. This service is priced separately. When the service is provided according to the contract and has the right to collect the consideration unconditionally, the Group recognized revenue and accounts receivable.

### C. Services revenue

When the Group acts in the capacity of an agent rather than as the principal in a transaction, the revenue recognized is the net amount of commission made by the Group.

The Group provides consulting and related management services to its customers. Revenue from providing services is recognized based on the actual service provided to the reporting date as a proportion of the total services to be provided. The proportion of services provided is determined based on the rendered services to date as a proportion of the total estimated rendered services of the transaction.

### (14) Employee benefits

#### A. Defined contribution plans

Obligations for contributions to the defined contribution pension plans are recognized as an employee benefit expense in profit or loss in the periods during which services are provided by employees.

#### B. Defined benefit plans

Short-term employee benefits are expensed as the related service is provided. A liability is recognized for the amount expected to be paid if the Group has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably.

### (15) Income taxes

Income taxes include both current taxes and deferred taxes. Except for items related to business combinations or recognized directly in equity or other comprehensive income, all current and deferred taxes are recognized in profit or loss.

Current taxes comprise the expected tax payables or receivables on the taxable profits (losses) for the year and any adjustment to the tax payable or receivable in respect of previous years. The amount of current tax payables or receivables are the best estimate of the tax amount expected to be paid or received that reflects uncertainty related to income taxes, if any. It is measured using tax rates enacted or substantively enacted at the reporting date.

Deferred taxes arise due to temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and their respective tax bases. Deferred taxes are recognized except for the following:

- A. temporary differences on the initial recognized of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable profits or losses;
- B. temporary differences related the investments in subsidiaries, associates and joint arrangement to the extent that the Group is able to control the timing of the reverse of the temporary differences and its probable that they will not reverse in the foreseeable future; and
- C. taxable temporary differences arising on the initial recognition of goodwill.

Deferred tax assets are recognized for the carry forward of unused tax losses, unused tax credits, and deductible temporary differences to the extent that it is probable that future taxable profits will be available against which they can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefits will be realized; such reductions are reversed when the probability of future taxable profits improves.

Deferred tax assets and liabilities are measured at tax rates that are expected to apply to the period when the asset is realized or the liability is settled, which is the tax rate that had been enacted by the end of the reporting period.

Deferred tax assets and liabilities are offset if the following criteria are met:

- A. the Group has a legally enforceable right to set off current tax assets against current tax liabilities; and
- B. the deferred tax assets and the deferred tax liabilities relate to income taxes levied by the same taxation authority on either:
  - (A) the same taxable entity; or
  - (B) different taxable entities which intend to settle current tax assets and liabilities on a net basis, or to realize the assets and liabilities simultaneously, in each future period in which significant amounts of deferred tax liabilities or assets are expected to be settled or recovered.

#### (16) Business Combinations

The Group accounts for business combinations using the acquisition method except for the group restructuring under common control. The goodwill arising from an acquisition is measured as the excess of (i) the consideration transferred (which is generally measured at fair value) and (ii) the amount of non-controlling interest in the acquiree, both over the identifiable net assets acquired at the acquisition date. If the amount calculated above is a deficit balance, the Company recognized that amount as a gain on a bargain purchase in profit or loss immediately after reassessing whether it has correctly identified all of the assets acquired and all of the liabilities assumed.

All acquisition-related transaction costs are expensed as incurred, except for the issuance of debt or equity instruments.

For each business combination, the Group measures any non controlling interests in the acquiree either at fair value or at the non controlling interest's proportionate share of the acquiree's identifiable net assets, if the non controlling interests are present ownership interests and entitle their holders to a proportionate share of the acquiree's net assets in the event of liquidation. Other components of non controlling interests are measured at their acquisition-date fair values, unless another measurement basis is required by the IFRSs endorsed by the FSC.

#### (17) Earnings per share

The Group discloses the Company's basic and diluted earnings per share attributable to ordinary shareholders of the Company. Basic earnings per share is calculated as the profit attributable to ordinary shareholders of the Company divided by the weighted average number of ordinary shares outstanding. Diluted earnings per share is calculated as the profit attributable to ordinary shareholders of the Company divided by the weighted average number of ordinary shares outstanding after adjustment for the effects of all potentially dilutive ordinary shares, such as convertible bonds and employee compensation.

#### (18) Operating segment information

An operating segment is a component of the Group that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the Group). Operating results of the operating segment are regularly reviewed by the Group's chief operating decision maker to make decisions about resources to be allocated to the segment and to assess its performance. Each operating segment consists of standalone financial information.

## 5. Significant accounting assumptions and judgments, and major sources of estimation uncertainty

The preparation of the consolidated financial statements in conformity with the Regulations and the IFRSs endorsed by the FSC requires management to make judgments, estimates (including climate-related risks and opportunities), and assumptions that affect the application of the accounting policies and the reported amount of assets, liabilities, income, and expenses. Actual results may differ from these estimates.

The management continues to monitor the accounting estimates and assumptions to ensure alignment with the Group's risk management and climate-related commitments. The management recognizes any changes in accounting estimates during the period and the impact of those changes in accounting estimates in the following period.

Information about judgments made in applying accounting policies that have the most significant effects on the amounts recognized in the consolidated financial statements : None.

Information about assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next financial year is as follows :

### A. Valuation of inventories

As inventories are stated at the lower of cost and net realizable value, the Group estimates the net realizable value of inventories for obsolescence and unmarketable items at the end of the reporting period and then writes down the cost of inventories to net realizable value. Please refer to note 6(4) for further description of the valuation of inventories.

### B. Impairment of goodwill

The assessment process for goodwill impairment relies on the Group's subjective judgment, including the identification of cash-generating units (CGUs), the allocation of goodwill to relevant CGUs, and the determination of the recoverable amount of the respective CGUs. For details on goodwill impairment assessment, please refer to Note 6(9).

## 6. Explanation of significant accounts

### (1) Cash and cash equivalents

	<u>December 31, 2025</u>	<u>December 31, 2024</u>
Petty cash	\$ 180	\$ 170
Cash in banks	464,359	588,172
	<u>\$ 464,539</u>	<u>\$ 588,342</u>

A. The above cash and cash equivalents were not pledged as collateral.

B. Time deposits which do not meet the definition of cash equivalents are accounted for under other financial assets-current. As of December 31, 2025 and 2024, the amount of time deposits were \$427,000 thousand and \$227,000 thousand, respectively.

C. Please refer to note 6(20) for the foreign currency risk and sensitivity analysis of the financial assets of the Group.

(2) Financial assets at fair value through other comprehensive income

Items	<u>December 31, 2025</u>	<u>December 31, 2024</u>
Equity instruments at fair value through other comprehensive income :		
Current	\$ 30,743	\$ 77,015
Non - current	179,145	186,213
	<u>\$ 209,888</u>	<u>\$ 263,228</u>

A. Equity instruments at fair value through other comprehensive income

The Group holds such equity investments as long-term strategic investment that is not held for trading purposes; thus, they are designated as equity investment measured at fair value through other comprehensive income.

In 2025 and 2024, the Group had sold part of the financial instruments at fair value through other comprehensive income with the fair value of \$46,047 thousand, and \$221,121 thousand, respectively, when the cumulative gain on disposal amounted to \$42,666 thousand and \$208,176 thousand, respectively, which has been transferred to retained earnings from other equity.

B. Please refer to note 6(20) for credit and market risk information.

C. The above financial assets were not pledged as collateral.

(3) Notes receivable and accounts receivable (including related parties)

	<u>December 31, 2025</u>	<u>December 31, 2024</u>
Notes receivable	\$ 13,208	\$ 11,048
Accounts receivable-measured at amortized cost	302,564	203,168
Less: Allowance for expected credit losses	( 3,429)	( 2,533)
	<u>\$ 312,343</u>	<u>\$ 211,683</u>

The Group applies the simplified approach to provide for its expected credit losses, which permit the use of lifetime expected loss provision for all receivables. To measure the expected credit losses, notes and accounts receivable have been grouped based on shared credit risk characteristics and the days past due, as well as forward looking information. The loss allowance provision was determined as follows:

	<u>December 31, 2025</u>		
	<u>Gross carrying amount</u>	<u>Weighted-average loss rate</u>	<u>Loss allowance provision</u>
Not past due	\$ 311,640	0.94%~1.45%	\$ 3,194
Past due 1~60 days	4,110	1%~12.53%	235
Past due 61~120 days	13	1%	-
Past due 121~180 days	9	2%	-
	<u>\$ 315,772</u>		<u>\$ 3,429</u>
	<u>December 31, 2024</u>		
	<u>Gross carrying amount</u>	<u>Weighted-average loss rate</u>	<u>Loss allowance provision</u>
Not past due	\$ 214,006	1%~1.29%	\$ 2,531
Past due 1~60 days	210	1%	2
Past due 61~120 days	-	-	-
	<u>\$ 214,216</u>		<u>\$ 2,533</u>

The movement in the allowance for notes and accounts receivable was as follows:

	<u>For the years ended December 31,</u>	
	<u>2025</u>	<u>2024</u>
Balance on January 1	\$ 2,533	\$ 1,770
Expected credit losses recognized	896	763
Balance on December 31	<u>\$ 3,429</u>	<u>\$ 2,533</u>

The aforementioned notes and trade receivables of the Group had not been pledged as collateral.

(4) Inventories

	<u>December 31, 2025</u>	<u>December 31, 2024</u>
Merchandise	\$ 60,916	\$ 111,535
Work in progress	56,898	42,946
Raw materials and supplies	41,614	40,544
Less: Allowance for inventory market decline and obsolescence	( 3,687)	( 18,950)
	<u>\$ 155,741</u>	<u>\$ 176,075</u>

The details of cost of goods sold were as follows:

	<u>For the years ended December 31,</u>	
	<u>2025</u>	<u>2024</u>
Cost of goods sold	\$ 658,239	512,736
Losses(gain) on inventory market decline and obsolescence	( 2,454)	20,218
	<u>\$ 655,785</u>	<u>\$ 532,954</u>

A. In the fiscal year 2025, previously recognized inventory write-downs were reversed as the net realizable value of inventories increased due to market demand for existing inventories.

B. As of December 31, 2025 and 2024, the aforesaid inventories were not pledged as collateral.

(5) Acquisition of subsidiary

On April 9, 2024 (the acquisition date), the Company acquired 51% of the outstanding shares of Top Pharma Medical-wares Co., Ltd. and TOP Biological Technology Company Limited. for \$301,451 thousand, thereby gaining control over these companies. Consequently, the Group's equity in Top Pharma Medical-wares Co., Ltd. and TOP Biological Technology Company Limited. increased to 51%. Top Pharma Medical-wares Co., Ltd. and TOP Biological Technology Company Limited. are engaged in the manufacturing and promotion of health food products.

The acquisition of control over Top Pharma Medical-wares Co., Ltd. and TOP Biological Technology Company Limited. has allowed the combined company to expand its operational scale, enhance its operational performance, and increase its competitiveness.

A. Transfer Pricing

	<u>Top Pharma Medical-wares</u>	<u>TOP Biological Technology</u>
Cash	<u>\$ 257,121</u>	<u>44,330</u>

B. Identifiable assets acquired and liabilities assumed

Fair value details of identifiable assets acquired and liabilities assumed as of the acquisition date are as follows :

	Top Pharma Medical-wares	TOP Biological Technology
Cash and cash equivalents	\$ 55,135	3,446
Notes receivable and accounts receivable	49,520	11,255
Inventories	5,185	7,584
Other financial assets	25,000	-
Property, plant and equipment	215	4,967
Right-of-use assets	4,955	1,949
Intangible assets	318	-
Other non-current assets	2,894	3,640
Notes payable and accounts payable	(37,105)	(11,391)
Lease liabilities	(5,049)	(2,023)
Current tax liabilities	(5,356)	(1,182)
Other liabilities	(8,397)	(554)
	<u>\$ 87,315</u>	<u>17,691</u>

### C. Goodwill

The goodwill recognized from the acquisition is as follows:

	Top Pharma Medical-wares	TOP Biological Technology
Transfer pricing	\$ 257,121	44,330
Add : Non-controlling interest ( measure net identifiable assets in proportion to non-controlling interests)	42,784	8,669
Less : Fair value of net identifiable assets	(87,315)	(17,691)
Goodwill	<u>\$ 212,590</u>	<u>35,308</u>

From April 9, 2024, the business performance of Top Pharma Medical-wares Co., Ltd. and TOP Biological Technology Company Limited. has been included in the consolidated comprehensive income statement of the Group. The net operating revenue contributed from April 9, 2024, to December 31, 2024, was \$273,144 thousand, and the net profit after tax was \$40,931 thousand.

If this acquisition had occurred on January 1, 2024, the pro forma net operating revenue of the Group from January 1, 2024, to December 31, 2024, would have been \$1,176,507 thousand, and the net profit after tax would have been \$138,290 thousand.

### (6) Material non-controlling interests of subsidiaries

The material non-controlling interests of subsidiaries were as follows:

<u>Subsidiaries</u>	<u>Main operation place</u>	<u>Percentage of non- controlling interests</u>	
		<u>December 31, 2025</u>	<u>December 31, 2024</u>
Chuang Yi Biotech Co. Ltd.	Taiwan	48.40%	48.40%
Top Pharma Medical-wares Co., Ltd.	"	49.00%	49.00%
TOP Biological Technology Company Limited.	"	-%	49.00%

The following information of the aforementioned subsidiaries have been prepared in accordance

with the Regulations Governing the Preparation of Financial Reports by Securities Issuers. Included in these information are the fair value adjustment made during the acquisition and relevant difference in accounting principles between the Group as at the acquisition date. Intragroup transactions were not eliminated in this information.

A. Chuang Yi Biotech Co. Ltd.'s collective financial information

	<u>December 31, 2025</u>	<u>December 31, 2024</u>
Current assets	\$ 402,654	339,124
Non-current assets	32,816	39,703
Current liabilities	(51,505)	(47,973)
Non- current liabilities	<u>-</u>	<u>(1,743)</u>
Net assets	<u>\$ 383,965</u>	<u>329,111</u>
Net assets attributed to non-controlling interests	<u>\$ 185,839</u>	<u>159,290</u>
	<u>For the years ended December 31,</u>	
	<u>2025</u>	<u>2024</u>
Sales revenue	<u>\$ 420,695</u>	<u>277,367</u>
Net income (loss)	54,475	1,284
Other comprehensive income	<u>378</u>	<u>73</u>
Comprehensive income	<u>\$ 54,853</u>	<u>1,357</u>
Net income (loss), attributable to non-controlling interests	<u>\$ 26,366</u>	<u>622</u>
Comprehensive income, attributable to non-controlling interests	<u>\$ 183</u>	<u>657</u>
Net cash flows from operating activities	\$ (13,738)	45,286
Net cash flows from investing activities	(146,458)	(1,564)
Net cash flows from financing activities	(1,712)	(2,000)
Effect of exchange rate changes on cash and cash equivalents	<u>-</u>	<u>72</u>
Net decrease in cash and cash equivalents	<u>\$ (161,908)</u>	<u>41,794</u>

B. Top Pharma Medical-wares Co., Ltd.'s collective financial information

	<u>December 31, 2025</u>	<u>December 31, 2024</u>
Current assets	\$ 230,753	192,868
Non-current assets	268,646	224,356
Current liabilities	(62,725)	(75,456)
Non- current liabilities	<u>(6,695)</u>	<u>(5,348)</u>
Net assets	<u>\$ 429,979</u>	<u>336,420</u>
Net assets attributed to non-controlling interests	<u>\$ 89,220</u>	<u>60,677</u>

	<b>For the years ended December 31, 2025</b>	<b>April 5 to December 31, 2025</b>
Sales revenue	<u>\$ 345,280</u>	<u>273,913</u>
Net income (loss)	45,292	36,515
Other comprehensive income	-	-
Comprehensive income	<u>\$ 45,292</u>	<u>36,515</u>
Net income (loss), attributable to non-controlling interests	<u>\$ 22,193</u>	<u>17,892</u>

	<b>For the years ended December 31,</b>	
	<b>2025</b>	<b>2024</b>
Net cash flows from operating activities	\$ 39,410	54,027
Net cash flows from investing activities	1,485	(9,478)
Net cash flows from financing activities	<u>(17,266)</u>	<u>(5,831)</u>
Net decrease in cash and cash equivalents	<u>\$ 23,629</u>	<u>38,718</u>

C. TOP Biological Technology Company Limited. 's collective financial information

	<b>December 31, 2024</b>
Current assets	\$ 29,892
Non-current assets	41,237
Current liabilities	(12,945)
Non- current liabilities	-
Net assets	<u>\$ 58,184</u>
Net assets attributed to non-controlling interests	<u>\$ 11,209</u>

	<b>From April 9, 2024 to December 31, 2024</b>
Sales revenue	<u>\$ 49,497</u>
Net income	5,186
Other comprehensive income	-
Comprehensive income	<u>\$ 5,186</u>
Net income attributable to non-controlling interests	<u>\$ 2,541</u>
Net cash flows from operating activities	\$ 2,077
Net cash flows from investing activities	(352)
Net cash flows from financing activities	<u>(1,364)</u>
Net increase in cash and cash equivalents	<u>\$ 361</u>

(7) Property, plant and equipment

The cost, depreciation, and impairment of the property, plant and equipment of the Group for the years ended December 31, 2025 and 2024, were as follows:

	<u>Land</u>	<u>Building and construction</u>	<u>Machinery equipment</u>	<u>Office equipment</u>	<u>Other equipment</u>	<u>Total</u>
Cost						
Balance on January 1, 2025	\$ 5,846	\$ 14,195	\$ 22,208	\$ 7,980	\$ 17,493	\$ 67,722
Additions	-	-	305	179	873	1,357
Disposals	-	-	(240)	(33)	(101)	(374)
Disposal of subsidiaries	-	-	(459)	-	-	(459)
Balance on December 31, 2025	<u>\$ 5,846</u>	<u>\$ 14,195</u>	<u>\$ 21,814</u>	<u>\$ 8,126</u>	<u>\$ 18,265</u>	<u>\$ 68,246</u>
Balance on January 1, 2024	\$ 5,846	\$ 14,195	\$ 12,845	\$ 9,641	\$ 10,641	\$ 53,168
Acquired through business acquisition	-	-	9,591	1,096	9,774	20,461
Additions	-	-	391	102	353	846
Disposals	-	-	(634)	(2,859)	(3,275)	(6,768)
Effect of movements in exchange rates	-	-	15	-	-	15
Balance on December 31, 2024	<u>\$ 5,846</u>	<u>\$ 14,195</u>	<u>\$ 22,208</u>	<u>\$ 7,980</u>	<u>\$ 17,493</u>	<u>\$ 67,722</u>
Accumulated depreciation and impairment:						
Balance on January 1, 2025	\$ -	\$ 10,756	\$ 16,357	\$ 6,868	\$ 13,752	\$ 47,733
Depreciation	-	393	2,226	631	855	4,105
Disposals	-	-	(240)	(33)	(101)	(374)
Disposal of subsidiaries	-	-	(436)	-	-	(436)
Balance on December 31, 2025	<u>\$ -</u>	<u>\$ 11,149</u>	<u>\$ 17,907</u>	<u>\$ 7,466</u>	<u>\$ 14,506</u>	<u>\$ 51,028</u>
Balance on January 1, 2024	\$ -	\$ 5,619	\$ 8,333	\$ 6,860	\$ 6,997	\$ 27,809
Acquired through business acquisition	-	-	5,580	938	8,761	15,279
Depreciation	-	871	2,623	1,208	1,268	5,970
Impairment loss	-	4,266	-	-	-	4,266
Disposals	-	-	(194)	(2,138)	(3,274)	(5,606)
Effect of movements in exchange rates	-	-	15	-	-	15
Balance on December 31, 2024	<u>\$ -</u>	<u>\$ 10,756</u>	<u>\$ 16,357</u>	<u>\$ 6,868</u>	<u>\$ 13,752</u>	<u>\$ 47,733</u>
Carrying amounts:						
Balance on January 1, 2025	<u>\$ 5,846</u>	<u>\$ 3,439</u>	<u>\$ 5,851</u>	<u>\$ 1,112</u>	<u>\$ 3,741</u>	<u>\$ 19,989</u>
Balance on December 31, 2025	<u>\$ 5,846</u>	<u>\$ 3,046</u>	<u>\$ 3,907</u>	<u>\$ 660</u>	<u>\$ 3,759</u>	<u>\$ 17,218</u>
Balance on January 1, 2024	<u>\$ 5,846</u>	<u>\$ 8,576</u>	<u>\$ 4,512</u>	<u>\$ 2,781</u>	<u>\$ 3,644</u>	<u>\$ 25,359</u>
Balance on December 31, 2024	<u>\$ 5,846</u>	<u>\$ 3,439</u>	<u>\$ 5,851</u>	<u>\$ 1,112</u>	<u>\$ 3,741</u>	<u>\$ 19,989</u>

A. Impairment loss

In the fiscal year 2024, due to the termination of the research and development project, the Group recognized an impairment loss of \$4,266 thousand on related property, plant, and equipment as of December 31, 2024. The impairment loss was recognized under other gains and losses in the comprehensive income statement.

B. Collateral

As of December 31, 2025 and 2024, the property, plant and equipment were not pledged as collateral.

(8) Right-of-use assets

The movements in the cost and depreciation of the leased buildings were as follows:

	<b>Building and construction</b>	<b>Transportation Equipment</b>	<b>Total</b>
Cost :			
Balance on January 1, 2025	\$ 14,928	15,291	30,219
Additions	6,086	4,365	10,451
Decrease	<u>(5,053)</u>	<u>(3,405)</u>	<u>(8,458)</u>
Balance on December 31, 2025	<b><u>\$ 15,961</u></b>	<b><u>16,251</u></b>	<b><u>32,212</u></b>
Balance on January 1, 2024	\$ 17,630	-	17,630
Acquired through business acquisition	5,053	15,982	21,035
Additions	9,874	8,915	18,789
Decrease	<u>(17,629)</u>	<u>(9,606)</u>	<u>(27,235)</u>
Balance on December 31, 2024	<b><u>\$ 14,928</u></b>	<b><u>15,291</u></b>	<b><u>30,219</u></b>
Accumulated depreciation :			
Balance on January 1, 2025	\$ 4,068	5,726	9,794
Depreciation	7,126	5,324	12,450
Decrease	<u>(5,053)</u>	<u>(3,405)</u>	<u>(8,458)</u>
Balance on December 31, 2025	<b><u>\$ 6,141</u></b>	<b><u>7,645</u></b>	<b><u>13,786</u></b>
Balance on January 1, 2024	\$ 10,314	-	10,314
Acquired through business acquisition	2,838	11,293	14,131
Depreciation	8,259	4,039	12,298
Decrease	<u>(17,343)</u>	<u>(9,606)</u>	<u>(26,949)</u>
Balance on December 31, 2024	<b><u>\$ 4,068</u></b>	<b><u>5,726</u></b>	<b><u>9,794</u></b>
Book value :			
Balance on December 31, 2025	<b><u>\$ 9,820</u></b>	<b><u>8,606</u></b>	<b><u>18,426</u></b>
Balance on January 1, 2024	<b><u>\$ 7,316</u></b>	<b><u>-</u></b>	<b><u>7,316</u></b>
Balance on December 31, 2024	<b><u>\$ 10,860</u></b>	<b><u>9,565</u></b>	<b><u>20,425</u></b>

(9) Intangible assets

The cost and amortization of the intangible assets of the Group for the years ended December 31, 2025 and 2024, were as follows:

	<u>Computer software</u>	<u>Patent and drug permit license</u>	<u>Drug distribution license</u>	<u>Goodwill</u>	<u>Others</u>	<u>Total</u>
Cost :						
Balance on January 1, 2025	\$ 6,880	14,600	70,000	247,898	77	339,455
Additions	2,586	3,298	-	-	-	5,884
Reclassification	-	6,122	-	-	-	6,122
Disposals	(501)	-	-	-	-	(501)
Balance on December 31, 2025	<u>\$ 8,965</u>	<u>24,020</u>	<u>70,000</u>	<u>247,898</u>	<u>77</u>	<u>350,960</u>
Balance on January 1, 2024	\$ 4,609	14,600	70,000	-	-	89,209
Acquired through business acquisition (Note 6(5))	1,253	-	-	247,898	87	249,238
Reclassification	1,018	-	-	-	-	1,018
Disposals	-	-	-	-	(10)	(10)
Balance on December 31, 2024	<u>\$ 6,880</u>	<u>14,600</u>	<u>70,000</u>	<u>247,898</u>	<u>77</u>	<u>339,455</u>
Accumulated amortisation and impairment losses:						
Balance on January 1, 2025	\$ 4,916	11,696	35,124	-	67	51,803
Amortisation	1,279	2,553	6,341	-	8	10,181
Disposals	(501)	-	-	-	-	(501)
Balance on December 31, 2025	<u>\$ 5,694</u>	<u>14,249</u>	<u>41,465</u>	<u>-</u>	<u>75</u>	<u>61,483</u>
Balance on January 1, 2024	\$ 2,568	4,223	28,782	-	-	35,573
Acquired through business acquisition (Note 6(5))	951	-	-	-	71	1,022
Amortisation	1,397	2,940	6,342	-	6	10,685
Disposal	-	-	-	-	(10)	(10)
Impairment loss	-	4,533	-	-	-	4,533
Balance on December 31, 2024	<u>\$ 4,916</u>	<u>11,696</u>	<u>35,124</u>	<u>-</u>	<u>67</u>	<u>51,803</u>
Book value						
Balance on December 31, 2025	<u>\$ 3,271</u>	<u>9,771</u>	<u>28,535</u>	<u>247,898</u>	<u>2</u>	<u>289,477</u>
Balance on January 1, 2024	<u>\$ 2,041</u>	<u>10,377</u>	<u>41,218</u>	<u>-</u>	<u>-</u>	<u>53,636</u>
Balance on December 31, 2024	<u>\$ 1,964</u>	<u>2,904</u>	<u>34,876</u>	<u>247,898</u>	<u>10</u>	<u>287,652</u>

A. Amortization expenses

Amortization expenses for intangible assets for the years ended December 31, 2025 and 2024 were recognized in the statement of comprehensive income, were as follows:

	<u>For the years ended December 31</u>	
	<u>2025</u>	<u>2024</u>
Operating expenses	<u>\$ 10,181</u>	<u>\$ 10,685</u>

## B. Impairment testing of goodwill

The goodwill of \$247,898 thousand arising from the acquisition of a subsidiary by the Group on April 9, 2024, is expected to expand the operational scale through the acquisition, thereby improving business performance and increasing competitiveness. According to International Accounting Standard No. 36, goodwill acquired in a business combination should be tested for impairment at least annually. The Group considers the acquired Top Pharma Medical-ware Co., Ltd. and TOP Biological Technology as a single cash-generating unit. The recoverable amount is determined based on value in use, which is estimated using the pre-tax cash flow forecast from the five-year financial budget approved by management. Cash flows beyond the five-year period are calculated using the long-term stable growth rate assumption evaluated by management, with an appropriate discount rate applied. As of December 31, 2025 and 2024, the key assumptions were a revenue growth rate of 7% and a discount rate of 10.35% and 10.57%.

Management believes that any reasonable possible changes in the key assumptions underlying the recoverable amounts of each cash-generating unit would not result in the carrying amounts exceeding their recoverable amounts. Based on the recoverable amounts calculated using the above key assumptions and compared with the carrying amounts of the assets used in operations and goodwill as of the evaluation date, there were no impairment of assets for the Group in the year 2025 and 2024.

## C. Impairment loss

In the year 2024, the recoverable amount of the pharmaceutical sales license was lower than its carrying value. As of December 31, 2024, the Group recognized an impairment loss of \$4,533 thousand for the related intangible assets, which was recorded under "Other gains and losses" in the consolidated statement of comprehensive income.

## D. Collateral

As of December 31, 2025 and 2024, the aforementioned intangible assets were not pledged as collateral.

## (10) Other current assets and other non-current assets

The details of the other current assets and other non-current assets were as follows:

	<u>December 31, 2025</u>	<u>December 31, 2024</u>
Other current financial assets	\$ 437,000	\$ 232,000
Other current assets	1,768	412
Long-term prepayments	4,699	6,417
Refundable deposits	9,609	8,750
	<u>\$ 453,076</u>	<u>\$ 247,579</u>

A. Other current financial assets were time deposits which did not meet the definition of cash equivalents. For further credit and market risk information, please refer to note 6(20).

B. The long-term prepayments primarily serve to acquire intangible assets, representing payments made before the intangible assets are ready for use. Please refer to Note 9 for detailed explanations regarding related unrecognized contractual commitments.

## (11) Other payables

The details of the short-term borrowings were as follows:

	<u>December 31, 2025</u>	<u>December 31, 2024</u>
Salaries and compensation of employees and directors	64,740	52,920
Research expenses	1,426	2,418
Commission	1,705	1,353
Others	40,191	34,017
	<u><b>108,062</b></u>	<u><b>90,708</b></u>

(12) Lease liabilities

The carrying amounts of lease liabilities were as follows:

	<u>December 31, 2025</u>	<u>December 31, 2024</u>
Current	<u>\$ 11,945</u>	<u>\$ 10,101</u>
Non-current	<u>\$ 6,695</u>	<u>\$ 10,330</u>

For the maturity analysis, please refer to note 6(20).

The amounts recognized in profit or loss were as follows:

	<u>For the years ended December 31</u>	
	<u>2025</u>	<u>2024</u>
Interest on lease liabilities	<u>\$ 797</u>	<u>\$ 441</u>
Variable lease payments not included in the measurement of lease liabilities	<u>\$ 300</u>	<u>\$ 300</u>
Expenses of short-term leases	<u>1,702</u>	<u>1,130</u>
Expenses relating to leases of low-value assets, excluding short-term leases of low-value assets	<u>\$ 186</u>	<u>\$ 252</u>

The amounts recognized in the statement of cash flows for the Group were as follows:

	<u>For the years ended December 31</u>	
	<u>2025</u>	<u>2024</u>
Total cash outflow for leases	<u>\$ 15,127</u>	<u>\$ 14,658</u>

A. Real estate leases

The Group leased buildings for its office and plant with lease term of 2 to 13.5 years. Some leases include an option to renew the lease for an additional period of the same duration after the end of the contract term.

The lease payment of the plant contract is calculated on basis of the purchase quantity of the plant leased by the Group during the lease period. It is a variable lease payment that is not included in the measurement of the lease liability. Therefore, the Group will pay the relevant lease payment during the lease period to recognize the expense.

B. Other leases

The Group lease office equipment with lease term of 0.5 to 5 years, these leases are leases of short-term or low-value items. The Group has elected not to recognize right-of-use assets and lease liabilities for these leases.

(13) Employee benefits

Defined contribution plans

The Group allocates 6% of each employee's monthly wages to the labor pension personal account

at the Bureau of Labor Insurance in accordance with the provisions of the Labor Pension Act. Under these defined contribution plans, the Group allocates a fixed amount to the Bureau of Labor Insurance without additional legal or constructive obligation.

The pension expenses of the Group under the defined contribution plan and have been contributed to the Bureau of Labor Insurance in 2025 and 2024 are as follows:

	<b>For the years ended December 31</b>	
	<b>2025</b>	<b>2024</b>
Cost of goods sold	\$ 376	\$ 110
Selling expenses	7,129	6,653
Administrative expenses	1,942	2,813
Research and development expenses	441	365
	<b>\$ 9,888</b>	<b>\$ 9,941</b>

(14) Income taxes

A. Income tax expense

The components of income tax in the years 2025 and 2024 are as follows:

	<b>For the years ended December 31</b>	
	<b>2025</b>	<b>2024</b>
Current income tax expense		
Current period	\$ 34,838	\$ 41,582
Adjustment for prior periods	39	209
Tax on undistributed surplus earnings	10,745	-
Deferred income tax expense	45,622	41,791
Origination and reversal of temporary differences	1,347	(2,506)
Income tax expenses	<b>\$ 46,969</b>	<b>\$ 39,285</b>

There was no income tax recognized directly in equity and other comprehensive income for 2025 and 2024.

Reconciliation of income tax and profit before tax for 2025 and 2024 is as follows:

	<b>For the years ended December 31</b>	
	<b>2025</b>	<b>2024</b>
Profit before income tax	\$ 234,787	\$ 173,433
Income tax using the Company's domestic tax rate	\$ 46,957	\$ 34,687
Tax-exempt income	(1,311)	(1,306)
Underestimation (Overestimation) in prior periods	39	209
Retained earnings surcharge	10,745	2,542
Alternative minimum tax	-	2,754
Others	(9,461)	399
	<b>\$ 46,969</b>	<b>\$ 39,285</b>

B. Unrecognized deferred tax assets

(i) Related to investments in subsidiaries

The consolidated entity is able to control the timing of the reversal of the temporary differences

associated with investments in subsidiaries as of December 31, 2025 and 2024. Also, management considers it probable that the temporary differences will not reverse in the foreseeable future. Hence, such temporary differences are not recognized under deferred tax assets. Details are as follows:

	<b>December 31, 2025</b>	<b>December 31, 2024</b>
Aggregate amount of temporary differences related to investments in subsidiaries	\$ -	\$ 14,811
Unrecognized deferred tax assets	<u>\$ -</u>	<u>\$ 2,962</u>

Because the Group is able to control the timing of the reversal of the temporary differences associated with investments and don't have the intention of reducing the capital or disposal in the foreseeable future, the Group don't recognize the deferred tax assets.

(ii) Related to deductible temporary differences and tax losses

	<b>December 31, 2025</b>	<b>December 31, 2024</b>
Tax effect of deductible temporary differences	\$ 3,213	\$ 7,983
Tax losses	46,304	52,761
	<u>\$ 49,517</u>	<u>\$ 60,744</u>

The R.O.C. Income Tax Act allows net losses, as assessed by the tax authorities, to offset taxable income over a period of ten years for local tax reporting purposes. Deferred tax assets have not been recognized in respect of these items because it is not probable that future taxable profit will be available against which the Group can utilize the benefits therefrom.

As of December 31, 2025, the information of the Group's unused tax losses for which no deferred tax assets were recognized are as follows:

<b>Year of loss</b>	<b>Unused tax loss</b>	<b>Expiry date</b>
2016(assessed)	13,450	2026
2019(assessed)	21,526	2029
2020(assessed)	175,037	2030
2022(assessed)	19,511	2032
2023(assessed)	1,995	2033
	<u>\$ 231,519</u>	

C. Recognized deferred tax assets

Changes in the amount of deferred tax assets for 2025 and 2024 were as follows:

	<b>Impairment Loss</b>	<b>Allowance for Price Decline in Inventorie</b>	<b>Others</b>	<b>Total</b>
Deferred tax assets				
Balance on January 1, 2025	(\$ 1,760)	(\$ 1,471)	(\$ 784)	(\$ 4,015)
Debit (Credit) in profit or loss	416	814	117	1,347
Balance on December 31, 2025	<u>(\$ 1,344)</u>	<u>(\$ 657)</u>	<u>(\$ 667)</u>	<u>(\$ 2,668)</u>
Balance on January 1, 2024	-	(\$ 1,311)	(\$ 198)	(\$ 1,509)
Debit (Credit) in profit or loss	(1,760)	(160)	(586)	(2,506)
Balance on December 31, 2024	<u>(\$ 1,760)</u>	<u>(\$ 1,471)</u>	<u>(\$ 784)</u>	<u>(\$ 4,015)</u>

D. Assessment of tax

The Group's tax returns for the years through 2023 were assessed by the Taipei National Tax Administration.

(15) Capital and other equity

As of December 31, 2025 and 2024, the authorized capital of the Group amounted to \$1,000,000, with par value of \$10 per share, which consisting of 100,000 thousand shares of ordinary stock. The paid-in capital was \$383,981 thousand which consisting of 38,398 thousand shares. All proceeds from shares issued have been collected.

A. Capital surplus

The balances of capital surplus as of December 31, 2025 and 2024 were as following:

	<u>December 31, 2025</u>	<u>December 31, 2024</u>
Share Capital	\$ 458,977	\$ 458,977
Others	636	577
	<u>\$ 459,613</u>	<u>\$ 459,554</u>

According to the R.O.C. Company Act, capital surplus can only be used to offset a deficit, and only the realized capital surplus can be used to increase the common stock or be distributed as cash dividends. The aforementioned realized capital surplus includes capital surplus resulting from premium on issuance of capital stock and earnings from donated assets received. According to the Regulations Governing the Offering and Issuance of Securities by Securities Issuers, capital increases by transferring capital surplus in excess of par value should not exceed 10% of the total common stock outstanding.

B. Retained earnings

The Group's article of incorporation stipulates that Group's net earnings should first be used to offset the prior years' deficits, if any, before paying any income taxes. Of the remaining balance, 10% is to be appropriated as legal reserve, until the accumulated legal reserve equals the Group's

paid-in capital. In addition, a special reserve in accordance with applicable laws and regulations shall also be set aside. Then, any remaining profit, together with any undistributed retained earnings, shall be distributed according to the proposal by the Board of Directors and submitted to the stockholders' meeting for approval.

To enhance the Group's financial structure and maintain investors' equity, the Group adopts a stable dividends policy in which earnings distribution cannot be less than 50% of distributable earnings, and cash dividends payment has to be over than 50% of the distribution.

(A) Legal reserve

When a Group incurs no loss, it may, pursuant to a resolution by a shareholders' meeting, distribute its legal reserve by issuing new shares or by distributing cash, and only the portion of legal reserve which exceeds 25% of capital may be distributed.

(B) Special reserve

The Group has set aside the same amount of special surplus reserve in accordance with the requirements of the Financial Supervisory Commission's Order No. 1010012865 dated April 6, 2012. When distributing the distributable surplus, the Group will record the deduction for other shareholders' equity that occurred in the current year. The difference between the net amount of the item and the special surplus reserve balance mentioned in the previous paragraph shall be included in the special surplus reserve from the profit and loss of the current period and the undistributed surplus of the previous period. The special surplus reserve shall not be distributed. If the amount of deductions from other shareholders' equity is subsequently reversed, the reversed portion of the earnings may be distributed.

(C) Earnings distribution

On May 28, 2025 and May 24, 2024, the general meeting of shareholders resolved to appropriate 2024 and 2023 earnings, respectively. The earnings were appropriated as follows:

	<b>For the years ended December 31,</b>			
	<b>2024</b>		<b>2023</b>	
	<b>Amount per share (dollars)</b>	<b>Total amount</b>	<b>Amount per share (dollars)</b>	<b>Total amount</b>
Dividends distributed to ordinary shareholders:				
Cash	\$ 2.12	<b>\$ 81,404</b>	\$ 1.28	<b>\$ 49,150</b>

On March 5, 2026, the board of directors proposed the 2025 earnings distribution to shareholders was as follows:

	<b>For the years ended December 31, 2025</b>	
	<b>Amount per share (dollars)</b>	<b>Total amount</b>
Dividends distributed to ordinary shareholders:		
Cash	\$ 2.61	<b>\$ 100,219</b>

C. Other equity interests

	Exchange differences on translation of foreign financial statements	Unrealized gains on financial assets measured at fair value through other comprehensive income	Total
Balance on January 1, 2025	(\$ 195)	\$ 67,774	\$ 67,579
Disposal of subsidiaries	195	-	195
Unrealized gains on financial assets measured at fair value through other comprehensive income	-	( 7,293)	( 7,293 )
Disposal of equity instruments measured at fair value through other comprehensive income	-	( 42,666)	( 42,666 )
At December 31, 2025	<u>\$ -</u>	<u>\$ 17,815</u>	<u>\$ 17,815</u>
Balance on January 1, 2024	(\$ 233)	\$ 55,793	\$ 55,560
Exchange differences on foreign operations	38	-	38
Unrealized gains on financial assets measured at fair value through other comprehensive income	-	220,157	220,157
Disposal of equity instruments measured at fair value through other comprehensive income	-	( 208,176)	( 208,176 )
At December 31, 2024	<u>(\$ 195)</u>	<u>\$ 67,774</u>	<u>\$ 67,579</u>

D. Non-controlling interests

	<b>For the years ended December 31</b>	
	<b>2025</b>	<b>2024</b>
At January 1, 2025	\$ 231,176	\$ 158,633
Attributable to non-controlling interests:		
Net income(loss)	48,558	21,055
Disposal of subsidiaries	185	-
Dividends distributed by subsidiaries to non-controlling interests	( 4,860 )	-
Exchange differences on translation of foreign financial statements	-	35
Changes in ownership interests in subsidiaries	-	51,453
At December 31, 2025	<u>\$ 275,059</u>	<u>\$ 231,176</u>

(16) Earnings per share

The calculation of basic earnings per share and diluted earnings per share were as follows:

	<b>For the years ended December 31,</b>	
	<b>2025</b>	<b>2024</b>
Basic earnings per share		
Net income attributable to ordinary shareholders	<u>\$ 139,260</u>	<u>\$ 113,093</u>
Weighted-average number of ordinary shares	<u>38,398</u>	<u>38,398</u>
	<u>\$ 3.63</u>	<u>\$ 2.95</u>
Diluted earnings per share		
Net income attributable to ordinary shareholders (after adjustment of dilutive potential ordinary shares)	<u>\$ 139,260</u>	<u>\$ 113,093</u>
Weighted-average number of ordinary shares	<u>38,398</u>	<u>38,398</u>
Effect of dilutive potential ordinary shares		
Effect of employee share bonus	<u>69</u>	<u>51</u>
Weighted-average number of ordinary shares (after adjustment of dilutive potential ordinary shares)	<u>38,467</u>	<u>38,449</u>
	<u>\$ 3.62</u>	<u>\$ 2.94</u>

(17) Revenue from contracts with customers

A. Disaggregation of revenue

	<b>For the years ended December 31,</b>	
	<b>2025</b>	<b>2024</b>
Major products/service lines:		
Pharmaceuticals	\$ 986,225	\$ 838,211
Vaccine	277,940	180,220
Test	59,522	44,734
Services	<u>12,836</u>	<u>52,551</u>
	<u>\$ 1,336,523</u>	<u>\$ 1,115,716</u>

B. Contract balances

	<b>December 31, 2025</b>	<b>December 31, 2024</b>	<b>January 1, 2024</b>
Notes receivable	\$ 13,208	\$ 11,048	\$ 14,471
Accounts receivable (included related parties)	302,564	203,168	195,631
Less: Allowance for expected credit losses	( 3,429)	( 2,533)	( 1,770)
Total	<u>\$ 312,343</u>	<u>\$ 211,683</u>	<u>\$ 208,332</u>
Contract liabilities	<u>\$ 3,242</u>	<u>\$ 1,039</u>	<u>\$ 1,842</u>

For details on notes receivable, accounts receivable and allowance for expected credit losses, please refer to note 6(3).

The contract liabilities primarily relate to the deferred recognition of revenue relating to customer loyalty programs and the unearned sales revenue, for which revenue is recognized when the performance obligation is satisfied. The amount of revenue recognized for the years ended December 31, 2025 and 2024 that were included in the contract liability balance at the beginning of the period were \$1,039 thousand and \$731 thousand, respectively.

(18) Remuneration to employees and directors

On May 28, 2025, the shareholders' meeting resolved to amend the Articles of Incorporation. According to the amended provisions, if the Group has profits in a given fiscal year, 2% to 8% shall be allocated as employee compensation (among which, compensation to grassroots employees shall not be less than 0.05%), and up to 2% may be allocated as remuneration for directors and supervisors. However, if the Group has accumulated losses, such losses must be covered before any allocation is made. The recipients of employee compensation, whether in stock or cash, may include employees of subsidiaries who meet certain criteria. Under the previous version of the Articles, if the Group had profits in a given fiscal year, 2% to 8% was to be allocated as employee compensation, to be distributed in stock or cash as resolved by the board of directors. The recipients could include employees of controlling or subsidiary companies who met certain criteria. The Group could also allocate up to 2% of such profits as directors' remuneration, which could only be distributed in cash. The distribution plans for employee compensation and directors' remuneration were to be reported to the shareholders' meeting. However, if there were accumulated losses, such losses must first be covered before allocating employee compensation and directors' remuneration according to the aforementioned percentages.

For the year ended December 31, 2025, the Group estimated its employee compensation and directors' remuneration amounting to \$3,609 thousand and \$1,985 thousand, respectively. For the year ended December 31, 2024, the Group estimated its employee compensation and directors' remuneration amounting to \$2,902 thousand and \$1,814 thousand. The estimated amounts mentioned above are calculated based on the net profit before tax, excluding the remuneration to employees and directors of each period, multiplied by the percentage of remuneration to employees, directors and supervisors as specified in the Group's articles of incorporation. These compensation and remunerations recognized as operating expenses during 2025 and 2024. Related information is available on the Market Observation Post System website.

The amounts, as stated in the financial statements, are identical to those of the actual distributions for 2025 and 2024.

(19) Non-operating income and expenses

A. Interest income

The details of interest income for the years ended December 31, 2025 and 2024 were as follows:

	<b>For the years ended December 31,</b>	
	<b>2025</b>	<b>2024</b>
Interest income from bank deposits	<b>\$ 8,274</b>	<b>\$ 5,456</b>

B. Other income

The details of other income for the years ended December 31, 2025 and 2024 were as follows:

	<b>For the years ended December 31,</b>	
	<b>2025</b>	<b>2024</b>
Rent income	\$ 136	384
Other income-other	2,120	1,918
	<b>\$ 2,256</b>	<b>\$ 2,302</b>

C. Other gains and losses

The details of other gains and losses for the years ended December 31, 2025 and 2024 were as follows:

	<b>For the year ended December 31,</b>	
	<b>2025</b>	<b>2024</b>
Foreign exchange gains (losses)	(\$ 60)	\$ 327
Dividend income	6,557	6,528
Losses on disposals of property, plant and equipment	-	( 867)
Gains on disposals of investments	1,113	
Impairment loss	-	( 8,799)
Others	( 926)	( 914)
Other gains and losses(net)	<b>\$ 6,684</b>	<b>\$ 3,725</b>

D. Finance costs

The details of finance costs for the years ended December 31, 2025 and 2024 were as follows:

	<b>For the year ended December 31,</b>	
	<b>2025</b>	<b>2024</b>
Other finance costs - Interest expenses	-	15
Other finance costs – Lease Liabilities	797	441
	<b>\$ 797</b>	<b>\$ 456</b>

(20) Financial instruments

A. Credit risk

(A) Credit risk exposure

The carrying amount of financial assets represents the maximum amount exposed to credit risk.

(B) Concentration of credit risk

The Group has a customer base that includes hospitals, medical centers, pharmacies, and clinics, which results in the Group having no significant concentration of credit risk. The Group regularly assesses the likelihood of accounts receivable collection and recognize allowance for doubtful accounts, and the impairment losses are always within management's expectations.

(C) Credit risk of accounts receivables and debt securities

For credit risk exposure of notes and accounts receivables, please refer to note 6(3).

Other financial assets at amortized cost includes other receivables and time deposits. All of these financial assets are considered to have low risk, and thus, the impairment provision recognized during the period was limited to 12 months expected losses. Regarding how the financial instruments are considered to have low credit risk, please refer to note 4(7). There were no recognition and reversal of impairment losses for the years ended December 31, 2025 and 2024. The balance as of December 31, 2025 and 2024 are both zero.

B. Liquidity risk

The following table shows the contractual maturities of financial liabilities, including estimated interest payments.

	<u>Carrying amount</u>	<u>Contractual cash flows</u>	<u>Within a year</u>	<u>2~3 years</u>	<u>4~5 years</u>
<b>December 31, 2025</b>					
Non-derivative financial liabilities					
Accounts payable (including related parties)	\$ 156,687	\$ 156,687	\$ 156,687	\$ -	\$ -
Lease liabilities	18,640	19,455	12,544	6,911	-
	<u>\$ 175,327</u>	<u>\$ 176,142</u>	<u>\$ 169,231</u>	<u>\$ 6,911</u>	<u>\$ -</u>
<b>December 31, 2024</b>					
Non-derivative financial liabilities					
Accounts payable (including related parties)	\$ 162,063	\$ 162,063	\$ 162,063	\$ -	\$ -
Lease liabilities	20,431	21,291	10,646	10,407	238
	<u>\$ 182,494</u>	<u>\$ 183,354</u>	<u>\$ 172,709</u>	<u>\$ 10,407</u>	<u>\$ 238</u>

The Group does not expect the cash flows included in the maturity analysis to occur significantly earlier or at significantly different amounts.

#### C. Currency risk

##### (A) Exposure to foreign currency risk

The Group's significant exposure to foreign currency risk were as follows:

	<u>December 31, 2025</u>			<u>December 31, 2024</u>		
	<u>Foreign currency</u>	<u>Exchange rate</u>	<u>TWD</u>	<u>Foreign currency</u>	<u>Exchange rate</u>	<u>TWD</u>
Financial assets						
Monetary items						
USD	\$ 116	31.430	\$ 3,644	\$ 169	32.785	\$ 5,554
HKD	343	4.038	1,385	342	4.222	1,445

##### (B) Sensitivity analysis

The Group's exposure to foreign currency risk arises from the translation of the foreign currency exchange gains and losses on cash and cash equivalents that is denominated in foreign currency. A strengthening (weakening) 1% of the TWD against the USD, CNY, and HKD as of December 31, 2025 and 2024 would have increased (decreased) the net profit after tax by \$40 thousand and \$56 thousand, respectively. The analysis assumes that all other variables remain constant and ignores any impact of forecasted sales and purchases. The analysis is performed on the same basis for both periods.

##### (C) Foreign exchange gain and loss on monetary items

Since the Group has many kinds of functional currency, the information on foreign exchange gain (loss) on monetary items is disclosed by total amount. For years 2024 and 2023, foreign exchange gain (loss) (including realized and unrealized portions) amounted to (\$60) thousand and \$327 thousand, respectively.

##### (D) Interest rate risk : None

#### D. Other market price risk

For the years ended December 31, 2025 and 2024, the sensitivity analysis for the changes in the securities price at the reporting date were performed using the same basis for the profit and loss

with all other variable factors remaining constant as illustrated below:

Prices of securities at the reporting date	For the years ended December 31,			
	2025		2024	
	Other comprehensive income after tax		Other comprehensive income after tax	
		Net income		Net income
Increasing 10%	\$ 20,989	\$ -	\$ 26,323	\$ -
Decreasing 10%	(\$ 20,989)	\$ -	(\$ 26,323)	\$ -

E. Fair value of financial instruments

(A) Categories of financial instruments and fair value hierarchy

The fair value of financial assets at fair value through other comprehensive income is measured on a recurring basis. The carrying amount and fair value of the Group's financial assets and liabilities, including the information on fair value hierarchy, were as follows; however, except as described in the following paragraphs, for financial instruments not measured at fair value whose carrying amount is reasonably close to the fair value, and lease liabilities, disclosure of fair value information is not required:

	December 31, 2025				
	Book Value	Fair Value			Total
		Level 1	Level 2	Level 3	
<b>Financial assets at fair value through other comprehensive income</b>					
Domestic listed stocks	\$ 179,145	\$ 179,145	\$ -	\$ -	\$ 179,145
Domestic OTC stocks	30,743	30,743	-	-	30,743
Foreign unlisted stocks	-	-	-	-	-
Subtotal	209,888	209,888	-	-	209,888
<b>Financial assets measured at amortized cost</b>					
Cash and cash equivalents	\$ 464,539	\$ -	\$ -	\$ -	\$ -
Notes and accounts receivable (including related parties)	312,343	-	-	-	-
Other receivables	1,978	-	-	-	-
Other financial assets	437,000	-	-	-	-
Refundable deposits	9,609	-	-	-	-
Subtotal	1,225,469	-	-	-	-
Total	\$ 1,435,357	\$ 209,888	\$ -	\$ -	\$ 209,888
<b>Financial liabilities at amortized cost</b>					
Notes and accounts payable (including related parties)	\$ 48,625	\$ -	\$ -	\$ -	\$ -
Other payables	108,062	-	-	-	-
Lease liabilities	18,640	-	-	-	-
Total	\$ 175,327	\$ -	\$ -	\$ -	\$ -

	<b>December 31, 2024</b>				
	<b>Book Value</b>	<b>Fair Value</b>			<b>Total</b>
		<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>	
<b>Financial assets at fair value through other comprehensive income</b>					
Domestic listed stocks	\$ 175,734	\$ 175,734	\$ -	\$ -	\$ 175,734
Domestic OTC stocks	77,015	77,015	-	-	77,015
Foreign unlisted stocks	10,479	-	-	10,479	10,479
Subtotal	<u>263,228</u>	<u>252,749</u>	<u>-</u>	<u>10,479</u>	<u>263,228</u>
<b>Financial assets measured at amortized cost</b>					
Cash and cash equivalents	\$ 588,342	\$ -	\$ -	\$ -	-
Notes and accounts receivable (including related parties)	211,683	-	-	-	-
Other receivables	2,182	-	-	-	-
Other financial assets	232,000	-	-	-	-
Refundable deposits	8,750	-	-	-	-
Subtotal	<u>1,042,957</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>
Total	<u><b>\$ 1,306,185</b></u>	<u><b>\$ 252,749</b></u>	<u><b>\$ -</b></u>	<u><b>\$ 10,479</b></u>	<u><b>\$ 263,228</b></u>
<b>Financial liabilities at amortized cost</b>					
Notes and accounts payable (including related parties)	\$ 71,355	\$ -	\$ -	\$ -	-
Other payables	90,708	-	-	-	-
Lease liabilities	20,431	-	-	-	-
Total	<u><b>\$ 182,494</b></u>	<u><b>\$ -</b></u>	<u><b>\$ -</b></u>	<u><b>\$ -</b></u>	<u><b>\$ -</b></u>

(B) Fair value hierarchy

The table below analyzes financial instruments carried at fair value by the levels in the fair value hierarchy. The different levels have been defined as follows:

- a. Level 1: quoted prices (unadjusted) in active markets for identified assets or liabilities.
- b. Level 2: inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).
- c. Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).

(C) Valuation techniques for financial instruments not measured at fair value

The Group estimates its financial instruments, that are not measured at fair value, by methods and assumption as follows:

Cash and cash equivalents, accounts receivables, other financial assets, notes payable and accounts payable are either close to their expiry date, or their future receivable or payable are close to their carrying value; thus, their fair value are estimated from the book value of the balance sheet date.

(D) Valuation techniques for financial instruments measured at fair value

Financial instruments traded in active markets are based on quoted market prices. The quoted

price of a financial instrument obtained from main exchanges and on-the-run bonds from Taipei Exchange can be used as a basis to determine the fair value of the listed companies' equity instrument and debt instrument of the quoted price in an active market.

If a quoted price of a financial instrument can be obtained in time and often from exchanges, brokers, underwriters, industrial union, pricing institute, or authorities, and such price can reflect those actual trading and frequently happen in the market, then the financial instrument is considered to have a quoted price in an active market. If a financial instrument is not in accord with the definition mentioned above, then it is considered to be without a quoted price in an active market. In general, market with low trading volume or high bid-ask spreads is an indication of a non-active market.

The fair value of the financial instruments held by the Group are determined by reference to the market quotation.

If the financial instruments held by the Group have no active market, their fair values are listed as follows according to their categories and attributes:

- Equity instruments without public quotation: The fair value is measured by using the transaction prices of the stocks of companies engaged in the same or similar businesses in the active market, the value multipliers implied by these prices, and related transaction information to determine the value of the financial instruments, as well as adjusted for considering liquidity discount.

(E) Transfer between levels

There was no change in valuation techniques for financial instruments measured at fair value for the years ended December 31, 2025 and 2024, so there was no transfer between levels.

(F) Reconciliation of level 3 fair values:

	<b>Fair value through other comprehensive income</b>
	<b>Equity instruments without quoted price</b>
Balance as of January 1, 2025	\$ 10,479
Recognized in other comprehensive income	( 10,479)
Balance as of December 31, 2025	<b>\$ -</b>
Balance as of January 1, 2024	\$ 9,017
Recognized in other comprehensive income	1,462
Balance as of December 31, 2024	<b>\$ 10,479</b>

(G) Quantified information on significant unobservable inputs (Level 3) used in fair value measurement

The Group's financial instruments that use Level 3 inputs to measure fair value include financial assets at fair value through other comprehensive income - equity investments.

The majority of the fair values of the Group are classified as Level 3 and involve only a single significant unobservable input, except for equity instrument investments without an active market, which involve multiple significant unobservable inputs. The significant unobservable inputs of the equity investments without an active market are individually, and there is no correlation between them.

Quantified information of significant unobservable inputs was as follows:

Item	Valuation technique	Significant unobservable inputs	Inter-relationship between significant unobservable inputs and fair value measurement
Financial assets at fair value through other comprehensive income – equity investments without an active market	Comparable companies method	• Discount for lack of market liquidity (as of December 31, 2025 and 2024, the rate were 41.4% and 30%)	• The estimated fair value would decrease if the discount for lack of market liquidity was higher.

(H) Fair value measurements in Level 3 – sensitivity analysis of reasonably possible alternative assumptions

The Group's measurement on the fair value of financial instruments is deemed reasonable. However, use of different valuation models or assumptions may lead to different results. The following is the effect on other comprehensive income from financial assets categorized within Level 3 if the inputs used to valuation models have changed:

	Input value	Degree of variation	Recognized in other comprehensive income	
			Favourable change	Unfavourable change
<b>December 31, 2025</b>				
Financial assets at fair value through other comprehensive income				
Equity investments without an active market	Market liquidity discount rate	1%	-	-
<b>December 31, 2024</b>				
Financial assets at fair value through other comprehensive income				
Equity investments without an active market	Market liquidity discount rate	1%	105 (	105)

The favorable and unfavorable effects represent the changes in fair value, and fair value is based on a variety of unobservable inputs calculated using a valuation technique. The analysis above only reflects the effects of changes in a single input, and it does not include the interrelationships with another input.

(21) Financial risk management

A. Overview

The Group is exposed to the following risks from its financial instruments:

- (A) Credit risk
- (B) Liquidity risk
- (C) Market risk

The following likewise discusses the Group's objectives, policies, and processes for measuring and managing the above mentored risks. For more disclosures about the quantitative effects of these risk exposures, please refer to the respective notes in the accompanying financial statements.

#### B. Structure of risk management

The objective of the Group's financial risk management is to manage foreign exchange risk, interest rate risk, credit risk and liquidity risk related to operating activities. In order to reduce adverse effects on the financial performance, the Group identifies, evaluates and hedges market uncertainties.

The important financial activities of the Group are reviewed in accordance with relevant regulations and internal control systems approved by the Board of Directors. When performing financial plan, the Group must comply with the overall financial risk management and the authorized procedure of financial operating.

#### C. Credit risk

Credit risk is the risk of financial loss to the Group if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the Group's receivables from customers and investments in debt securities.

##### (A) Accounts receivable and other receivables

The Group's credit policy is to transact with creditworthy customers and to obtain collateral to mitigate risks arising from financial loss due to default. The Group transacts with customers with credit ratings equivalent to investment grade, and such ratings are provided by independent rating agencies. Where it is not possible to obtain such information, the Group assesses the ratings based on other publicly available financial information and the records of transactions with its customers. The Group continuously monitor the exposure to credit risk and counterparty credit ratings, and to evaluate the customers' credit ratings and credit limits via annual review and approval by the finance department to manage the credit exposure.

The Group did not have any collateral or other credit enhancement to avoid credit risk of the financial assets.

##### (B) Investments

The exposure to credit risk for the bank deposits, fixed income investments, and other financial instruments, is measured and monitored by the Group's finance department. The Group only deals with banks, other external parties, corporate organizations, government agencies and financial institutions with good credit rating. The Group does not expect any of the counterparties above to fail in meeting their obligations; hence, there is no significant credit risk arising from these counterparties.

##### (C) Guarantees

As of December 31, 2025 and 2024, the Group did not provide any endorsement or guarantee.

#### D. Liquidity risk

Liquidity risk is the risk that the Group will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Group's approach to managing liquidity is to ensure, as far as possible, that it always has sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Group's reputation.

E. Market risk

Market risk is the risk that changes in market prices, such as foreign exchange rates, interest rates, and equity prices, will affect the Group's income or the value of its holdings of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimizing the return.

(22) Capital management

Based on the characteristics of the current operating industry and the future development of the Group, and considered changes in the external environment, the Group plans the requirement of working capital, research and development expenses, and dividend payments in the future to ensure that the Group to continue to operate, to provide a return on shareholders, to maintain the interests of other stakeholders and to maintain an optimal capital structure to enhance shareholder value.

In order to maintain or adjust the capital structure, the Group may adjust the dividend payment to the shareholders, issue new shares, reduce the capital for redistribution to shareholders, or buy back the stocks of the Group.

The Group and other entities in the same industry use the debt-to-equity ratio to manage capital. This ratio is the total net debt divided by the total capital. The net debt from the balance sheet is derived from the total liabilities less cash and cash equivalents. The total amount of capital represents all the equity components (that is, share capital, capital surplus, retained earnings, and other equity) plus net debt.

The Group's debt-to-equity ratio as of December 31, 2025 and 2024 were as follows:

	<u>December 31, 2025</u>	<u>December 31, 2024</u>
Total liabilities	\$ 233,786	\$ 219,225
Less: cash and cash equivalents	( 464,539)	( 588,342)
Net debt	( 230,753)	( 369,117)
Total capital	1,717,668	1,622,968
Adjusted capital	<u>\$ 1,486,915</u>	<u>\$ 1,253,851</u>
Debt to equity ratio	<u>( 15.52% )</u>	<u>( 29.44% )</u>

As of December 31, 2025, the debt-to-equity ratio increased primarily due to the equity increase resulting from the business combination.

(23) Investing and financing activities not affecting current cash flow

The Group's investing and financing activities which did not affect the current cash flow for the years ended December 31, 2025 and 2024, were as follows:

A. Acquisition of right-of-use assets under leases, please refer to note 6(8).

B. Reconciliation of liabilities arising from financing activities were as follows:

	<u>January 1,</u> <u>2025</u>	<u>Cash flow</u>	<u>Non-cash</u> <u>changes</u>	<u>December 31,</u> <u>2025</u>
			<u>Others</u>	
Lease liabilities	<u>\$ 20,431</u>	<u>(\$ 12,242)</u>	<u>\$ 10,451</u>	<u>\$ 18,640</u>

	<b>January 1, 2024</b>	<b>Cash flow</b>	<b>Non-cash changes</b>	<b>December 31, 2024</b>
			<b>Others</b>	
Lease liabilities	<b>\$ 7,397</b>	<b>(\$ 12,535)</b>	<b>\$ 25,569</b>	<b>\$ 20,431</b>

## 7. Related-party transactions

### (1) Parent company and ultimate controlling company

TTY Biopharm Company Limited is both the parent company and the ultimate controlling party of the Group. It owns 56.48 % of all shares outstanding of the Group, and has issued the Consolidated Financial Statements Available for Public Use.

### (2) Names and relationship with related parties

The followings are entities that have transactions with related party during the periods covered in the financial statements.

<u>Name of related parties</u>	<u>Relationship with the Group</u>
TTY Biopharm Company Limited	Parent company
American Taiwan Biopharm(Thailand)	Other related party

### (3) Significant related-party transactions

#### A. Operating revenue

The amounts of significant sales by the Group to its related parties were as follows:

	<b>For the years ended December 31,</b>	
	<b>2025</b>	<b>2024</b>
Parent company- TTY Biopharm Company Limited	\$ 16,439	\$ 8,026
Other related parties	9,142	6,704
	<b>\$ 25,581</b>	<b>\$ 14,730</b>

The selling price and payment terms to related parties were not significantly different from those of sales to third parties. The collection terms for sales to related parties were month-end 60-90 days, or 14 days after the date of shipment. The collection terms for commission were month-end 30 and 90 days.

#### B. Purchases

The amounts of significant purchases by the Group from related parties were as follows:

	<b>For the years ended December 31,</b>	
	<b>2025</b>	<b>2024</b>
Parent company - TTY Biopharm Company Limited	<b>\$ 333,374</b>	<b>\$ 256,782</b>

The pricing and payment terms with related parties were not materially different from those of purchases with third parties. The payment terms for purchases from related parties were month-end 30-90 days.

C. Receivables from related parties

The amounts of receivables from related parties were as follows:

<u>Items</u>	<u>Related Party Categories</u>	<u>December 31, 2025</u>	<u>December 31, 2024</u>
Accounts receivable	Parent company	\$ 7,365	\$ 1,177
Other receivables	Parent company	\$ 433	\$ -

D. Payables to related parties

The amounts of payables to related parties were as follows:

<u>Items</u>	<u>Related Party Categories</u>	<u>December 31, 2025</u>	<u>December 31, 2024</u>
	Parent company - TTY Biopharm Company Limited		
Accounts payable- related parties		\$ 25,851	\$ 36,766
Other payables	Parent company	3,046	1,918
		<u>\$ 28,897</u>	<u>\$ 38,684</u>

F. Lease

The Group leases offices and equipments from the parent company, and the details were as follows:

<u>Items</u>	<u>December 31, 2025</u>	<u>December 31, 2024</u>
Guarantee deposits paid	\$ 838	\$ 838
Lease liabilities	\$ 4,982	\$ 9,875

  

<u>Items</u>	<u>December 31, 2025</u>	<u>December 31, 2024</u>
Interest paid	\$ 135	\$ 41
Interest received	\$ 14	\$ -

G. Other expenses

For the years ended December 31, 2025 and 2024, the operating expenses paid by the Group to the parent company were as follows:

<u>Name of related parties</u>	<u>December 31, 2025</u>	<u>December 31, 2024</u>
Operating expenses	\$ 7,431	\$ 6,913

H. Other income

For the years ended December 31, 2025 and 2024, the non-operating income recognized by the Group from services rendered to related parties (recorded under "Other income") were as follows:

<u>Name of related parties</u>	<u>December 31, 2025</u>	<u>December 31, 2024</u>
Other income	\$ 364	\$ -

(4) Key management personnel compensation

	<b>For the years ended December 31,</b>	
	<b>2025</b>	<b>2024</b>
Short-term employee benefits	\$ 48,004	\$ 42,986
Post-employment benefits	1,133	1,252
	<b><u>\$ 49,137</u></b>	<b><u>\$ 44,238</u></b>

**8. Pledged assets:**

<b>Items</b>	<b>Pledged Collateral</b>	<b>December 31, 2025</b>	<b>December 31, 2024</b>
Other financial assets-non current	Agency distribution payment	<b><u>\$ 10,000</u></b>	<b><u>5,000</u></b>

**9. Significant commitments and contingencies**

As of December 31, 2025 and 2024, the unrecognized contractual commitments of the Group were as follows:

	<b>December 31, 2025</b>	<b>December 31, 2024</b>
Contract with other units for research and development	<b><u>\$ 21,038</u></b>	<b><u>\$ 19,099</u></b>
Acquisition of intangible assets	<b><u>6,392</u></b>	<b><u>4,286</u></b>

**10. Losses due to major disasters: None.**

**11. Subsequent events: None.**

**12. Others**

(1) The followings are the summary of employee benefits, depreciation, and amortization by function for the years ended December 31, 2025 and 2024:

By function	<b>For the years ended December 31,</b>					
	<b>2025</b>			<b>2024</b>		
	<b>Operating cost</b>	<b>Operating expenses</b>	<b>Total</b>	<b>Operating cost</b>	<b>Operating expenses</b>	<b>Total</b>
By item						
Employee benefits						
Salary	8,081	228,756	236,837	3,504	198,846	202,350
Labor and health insurance	741	16,100	16,841	224	15,054	15,278
Pension	376	9,512	9,888	110	9,831	9,941
Others	275	7,653	7,928	102	6,732	6,834
Depreciation	3,131	13,424	16,555	1,724	16,544	18,268
Amortization	-	10,181	10,181	-	10,685	10,685

(2) Others:

The Group donated \$16,790 thousand and \$13,503 thousand to related medical foundation and associations to support non-profit organizations developing drugs, promoting disease prevention and correct dosages for the year ended December 31, 2025 and 2024, respectively.

### 13. Other disclosures

#### (1) Information on significant transactions

The following is the information on significant transactions required by the “Regulations Governing the Preparation of Financial Reports by Securities Issuers” for the Group for the year ended December 31, 2025 and 2024, respectively.

A. Loans to other parties: None.

B. Guarantees and endorsements for other parties: None.

C. Securities held as of December 31, 2025 (excluding those investments in subsidiaries, associates and joint ventures):

(In Thousands of New Taiwan Dollars/Thousands shares)

Name of holder	Category and name of security	Relationship with Group	Account title	Ending balance				Highest percentage of ownership or investment situation during the period	Note
				Shares/ Units	Carrying value	Percentage of ownership (%)	Fair value		
TSH Biopharm Corporation Ltd.	Lumosa Therapeutics Co., Ltd.	-	Current financial assets at fair value through other comprehensive income	158	30,743	0.09%	30,743	0.18%	
"	Fubon Financial Holding Co., Ltd. Preferred stock B	-	Non-current financial assets at fair value through other comprehensive income	2,500	154,250	0.38%	154,250	0.38%	
"	Union Bank of Taiwan Preferred stock A	-	"	400	21,800	0.20%	21,800	0.20%	
"	Fubon Financial Holding Co., Ltd. Preferred stock C	-	"	58	3,095	0.02%	3,095	0.02%	
"	CellMax Ltd.	-	"	1,593	-	-%	-	-%	

D. Related-party transactions for purchases and sales with amounts exceeding the lower of NT\$100 million or 20% of the capital stock:

(Amounts in Thousands of New Taiwan Dollars)

Purchaser /seller	Counterparty	Relationship with the counterparty	Transaction				Differences in transaction term compared to third party transactions		Notes/accounts receivable (payable)		Footnote
			Purchases (sales)	Amount	Percentage of total purchases (sales)	Credit term	Unit price	Credit term	Balance	Percentage of total notes/accounts receivable (payable)	
TSH Biopharm Corporation Ltd.	TTY Biopharm Company Limited	Parent company	Purchases	84,485	29.45%	month-end 30 days	Normal	Not significantly different from general manufacturers.	(10,915)	(53.52)%	
Chuang Yi Biotech Co. Ltd.	TTY Biopharm Company Limited	Ultimate parent company	Purchases	248,889	96.10%	month-end 90 days	Normal	Not significantly different from general manufacturers.	(14,936)	(89.66)%	

E. Receivables from related parties with amounts exceeding the lower of NT\$100 million or 20% of the capital stock: None.

## F. Business relationships and significant intercompany transactions:

Number	Trader's name	Counterparty	Relationship with the trader	Transaction details			
				Account title	Amount	Transaction conditions	Ratio of combined total revenue or total assets
0	TSH Biopharm Corporation Ltd.	Top Pharma Medical-wares Co., Ltd.	1	Sales revenue	86,340	According to the contract terms	6.46%
0	TSH Biopharm Corporation Ltd.	Top Pharma Medical-wares Co., Ltd.	1	Notes receivable	7,712	"	0.40%
0	TSH Biopharm Corporation Ltd.	Top Pharma Medical-wares Co., Ltd.	1	Accounts receivable	9,374	"	0.48%

Note 1 ∙ The numbering format is as follows :

- 0 Representing the parent company.
- Subsidiaries numbered sequentially starting from Arabic numeral 1.

Note 2 ∙ Types of relationships with the trader are indicated as follows:

- Parent company to subsidiary.
- Subsidiary to parent company
- Subsidiary to subsidiary

Note 3 ∙ When preparing consolidated financial statements, all amounts have been fully offset.

Note 4 ∙ Individual amounts not exceeding \$1,000 thousand will not be disclosed, and their corresponding transactions will no longer be disclosed.

## (2) Information on investees:

The investment information of the Group for the year ended 2025 is as follows:

(In Thousands of New Taiwan Dollars/Thousands shares)												
Investor Company	Investee Company	Location	Main Businesses and Products	Original Investment Amount		Balance as of December 31, 2025			Highest percentage of ownership or investment situation during the period	Net Income (losses) of the investee	The amount of investment gain or loss recognized in the current period	Footnote
				December 31, 2025	December 31, 2024	Shares	Percentage of Ownership	Carrying Value				
TSH Biopharm Corporation Ltd.	Chuang Yi Biotech Co. Ltd.	Taiwan	Selling of health food	200,262	200,262	16,590	51.60%	198,126	51.60%	54,475	28,110	
TSH Biopharm Corporation Ltd.	Top Pharma Medical-wares Co., Ltd.	Taiwan	Selling of medicine and dietary supplement	301,451	257,121	3,794	51.00%	340,077	51.00%	45,292	23,098	
TSH Biopharm Corporation Ltd.	TOP Biological Technology Company Limited.	Taiwan	Food manufacturing industry	-	44,330	-	-%	-	-%	-	-	
Chuang Yi Biotech Co. Ltd.	Immortal Fame Global Ltd.	SAMOA	General export trade and investment in various production enterprises	-	16,820	-	-%	-	-%	-	-	

Note 1: The aforementioned transactions were eliminated in the preparation of consolidated financial statements.

Note 2: Changes in subsidiaries included in the consolidated financial statements are detailed in Note 4(2).

## (3) Information on investment in mainland China: None.

## 14. Segment information

### (1) General information

The Group's operating segments required to be disclosed are categorized as Domestic Cardiovascular Business Unit, Gastrointestinal Drugs Business Unit, and Investment Business Unit, etc.

The segments' profit is measured at profit before tax. The Group assesses performance of the

segments based on the segments' profit. The operating segments' accounting policies are similar to those described in Note 4 "significant accounting policies"

(2) Information about reportable segments and their measurement and reconciliations

The Group's operating segment information and reconciliation are as follows:

	<b>Domestic Cardiovascular and Gastrointestinal Drugs</b>	<b>Investment</b>	<b>Adjustment and elimination</b>	<b>Total</b>
<b>2025</b>				
Revenue				
Revenue from External Customer	\$ 570,607	\$ 765,916	\$ -	\$ 1,336,523
Interdepartmental revenue	86,340	58	( 86,398 )	-
Interest revenue	<u>5,084</u>	<u>3,190</u>	<u>-</u>	<u>8,274</u>
Total	<u><u>\$ 662,031</u></u>	<u><u>\$ 769,164</u></u>	<u><u>( \$ 86,398 )</u></u>	<u><u>\$ 1,344,797</u></u>
Interest Expense	137	706	( 46 )	797
Depreciation and amortization	9,712	18,622	( 1,598 )	26,736
Share of Profit or Loss of Associates & Joint Ventures Accounted for Using Equity Method	51,208	-	( 51,208 )	-
Reportable segment profit or loss	<u><u>\$ 174,485</u></u>	<u><u>\$ 111,510</u></u>	<u><u>( \$ 51,208 )</u></u>	<u><u>\$ 234,787</u></u>
Investments accounted for using equity method	538,203	-	( 538,203 )	-
<b>Reportable segment assets</b>	<u><u>\$ 1,557,349</u></u>	<u><u>\$ 932,307</u></u>	<u><u>( \$ 538,203 )</u></u>	<u><u>\$ 1,951,453</u></u>
	<b>Domestic Cardiovascular and Gastrointestinal Drugs</b>	<b>Investment</b>	<b>Adjustment and elimination</b>	<b>Total</b>
<b>2024</b>				
Revenue				
Revenue from External Customer	\$ 565,240	\$ 550,476	\$ -	\$ 1,115,716
Interdepartmental revenue	63,268	803	( 64,071 )	-
Interest revenue	<u>2,900</u>	<u>2,556</u>	<u>-</u>	<u>5,456</u>
Total	<u><u>\$ 631,408</u></u>	<u><u>\$ 553,835</u></u>	<u><u>( \$ 64,071 )</u></u>	<u><u>\$ 1,121,172</u></u>

	<b>Domestic Cardiovascular and Gastrointestinal Drugs</b>	<b>Investment</b>	<b>Adjustment and elimination</b>	<b>Total</b>
Interest Expense	55	413	( 12 )	456
Depreciation and amortization	11,753	17,630	( 430 )	28,953
Share of Profit or Loss of Associates & Joint Ventures Accounted for Using Equity Method	21,930	( 21,930 )	-	-
Impairment of assets	8,799	-	8,799	17,598
Reportable segment profit or loss	<u>\$ 118,190</u>	<u>\$ 55,243</u>	<u>\$ -</u>	<u>\$ 173,433</u>
Investments accounted for using equity method	491,401	-	( 491,401 )	-
<b>Reportable segment assets</b>	<u>\$ 1,483,408</u>	<u>\$ 850,186</u>	<u>( \$ 491,401 )</u>	<u>\$ 1,842,193</u>

(3) Product and service information

The Group's revenue comes solely from a single product of pharmaceuticals and chemical drugs, as well as biotechnology services.

(4) Geographic information

The Group mainly sells domestically.